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Abstract 
Background: Identifying the mechanistic pathways potentially associated with incident HF may 
provide a basis for novel preventive strategies. 
Methods and Results: To identify proteomic biomarkers and the potential underlying mechanistic 
pathways that may be associated with incident HF defined as first hospitalization for HF, a nested-
matched case-control design was used with cases (incident HF) and controls (without HF) selected 
from 3 cohorts (>20,000 individuals). Controls were matched on cohort, follow-up time, age, and sex. 
Two independent sample sets (a “discovery” set, with 286 cases and 591 controls and a “replication” 
set with 276 cases and 280 controls) were used to discover and replicate the findings. 252 circulating 
proteins in the plasma were studied. Adjusting for the matching variables age, sex, and follow-up time 
(and correcting for multiplicity of tests), 89 proteins were found to be associated with incident HF in 
the discovery phase, of which 38 were also associated with incident HF in the replication phase. 
These 38 proteins pointed to 4 main network clusters underlying incident HF: 1) inflammation and 
apoptosis, indicated by the expression of the TNF-family members; 2) extracellular matrix 
remodelling, angiogenesis and growth, indicated by the expression of proteins associated with 
collagen metabolism, endothelial function and vascular homeostasis; 3) blood pressure regulation, 
indicated by the expression of natriuretic peptides and proteins related to the renin angiotensin 
aldosterone system; and 4) metabolism, associated with cholesterol and atherosclerosis. 
Conclusion: Clusters of biomarkers associated with mechanistic pathways leading to HF were 
identified linking inflammation, apoptosis, vascular function, matrix remodelling, blood pressure 
control and metabolism. These findings provide important insight on the pathophysiological 
mechanisms leading to HF. 
 
Key-words: incident heart failure; proteomics; ageing; prognostic; mechanistic pathways 
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Introduction 
Heart failure (HF) is a major cause of morbidity and mortality worldwide and the most frequent cause 
of hospitalization for patients over 65 years of age1 2, 3. The incidence and prevalence of HF are 
increasing due to the ageing of the population as well as rising rates of HF risk factors such as 
diabetes, obesity, and hypertension3-6. Identifying mechanistic pathways leading to HF may help 
improve preventive strategies7. 
In the last decade, circulating biomarkers, such as N-terminal pro brain natriuretic peptide 
(NT-proBNP), have been studied for prediction of incident HF7-10. A recently published study10, also 
investigated the association of multiple proteins with incident HF for “prediction” purposes; these 
proteins (n=80) added little gain to the prognostic model including natriuretic peptides. However, 
above and beyond “prediction”, biomarkers may reflect pathophysiological processes and thus may 
help in assessing the underlying pathways that contribute to the progression towards HF. Investigating 
the pathophysiological processes may provide potential targets for future therapies. For this purpose, 
knowledge-based network analysis with induced network approach may help identify the links among 
the identified protein biomarkers, providing the basis for the identification of the underlying pathways 
leading to HF11.   
The Heart OMics in AGEing consortium (HOMAGE; NCT02556450) is an EU funded 
program that aims to identify and validate omics biomarkers associated with incident HF in order to 
potentially develop new and personalized preventive strategies. We report proteomics results, based 
on assays of 252 plasma proteins related to cardiovascular disease and inflammation, testing the 
associations of these proteins with incident HF, applying knowledge-based network analysis in order 
to identify mechanistic pathways underlying the progression to HF.   
 
Methods 
Study Population 
The HOMAGE-consortium included 20 completed and ongoing studies conducted in eight European 
countries that enrolled healthy subjects, patients with HF and patients at high risk of CV disease, all of 
which were pooled in a common database12. From the HOMAGE population with >20,000 patients, 
we identified cohorts in whom individuals had been followed-up until first hospitalisation for heart 
failure (HF).  Patients from two suitable cohorts and one clinical trial population were identified: 
PREDICTOR13, HEALTH-ABC14, and PROSPER12, 15. Patients with a history of HF at baseline were 
excluded. We then employed a nested matched case-control design were individuals who developed 
HF were considered to be at-risk i.e. eligible to be selected as controls up until the time they became a 
case16: a total of 852 incident HF cases were identified (574 in HEALTH-ABC, 234 in PROSPER, 44 
in PREDICTOR); within the respective cohorts controls were selected, matched age, sex, and follow-
up time (defined as time of incident HF from entry to the cohort). The final numbers after the 
matching procedures are provided below. 
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The data that support the findings of this study are available from the corresponding author 
upon reasonable request. 
Discovery and replication 
The HOMAGE study had two independent phases: discovery and replication. For the discovery phase,  
we selected 300 cases and 599 controls (1 case only had 1 match) randomly selected without 
replacement in a 1:2 proportion17-19; due to 22 missing or poor-quality samples, the final match was 
286 cases to 591 controls.  For replication we selected 315 cases and 315 controls randomly selected 
without replacement in a 1:1 proportion; due to 74 missing or poor-quality samples, the final match 
was 276 cases to 280 controls.  
The study was conducted in accordance with the Declaration of Helsinki and approved by 
each site ethics committees. All participants provided written informed consent. 
Outcome 
The outcome was incident HF which was defined as first hospitalisation for HF as primary admission 
diagnosis (adjudicated by the investigators of the respective cohorts). 
Sample handling 
All sample shipments and sample data acquisition within the HOMAGE consortium are according to 
predefined standard operating procedures and material transfer agreements to maintain uniformity. 
Supplemental Figure 1 shows the sample handling and storage per cohort and the sample flow until 
protein measurement at the TATAA Biocenter (Gothenburg, Sweden). Aliquoting of the samples at 
Biobank Maastricht was performed using a multi-pipette in 1 run to reduce freeze/thaw cycles and 
batch effects. The entire sampling handling/protein measurement was carried out fully blind to case 
control status. The cases and controls were separately identified and selected by the study statistician. 
All patient information was then removed and a randomly sorted list of patient/sample IDs for each 
cohort was sent to Maastricht University Medical Center (MUMC). 
Assays and studied biomarkers 
Baseline plasma samples were analysed for protein biomarkers by the TATAA-biocenter using the 
Olink Proseek® Multiplex cardiovascular (CVD) II, CVD III, and inflammation panels. These panels 
were selected by the well-balanced inclusion of proteins with already established associations with 
CV disease and HF (e.g. BNP, ST2, GDF15) and others with less well-established associations (e.g. 
TWEAK, PON3). The assay use a proximity extension assay (PEA) technology20, where 92 
oligonucleotide-labelled antibody probe pairs per panel are allowed to bind to their respective targets 
in the sample in 96-well plate format. When binding to their correct targets, they give rise to new 
DNA amplicons with each ID-barcoding their respective antigens. The amplicons are subsequently 
quantified using a Fluidigm BioMark™ HD real-time PCR platform. The platform provides log2-
normalized protein expression (NPX) data. A detailed description of the Olink® technology is 
depicted in the Supplemental Addenda 1. For 9 proteins measured in both the inflammation panel 
and CVD panels, the one from CVD panels was used for further data analyses (the results for these 
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proteins were strongly correlated ≥0.9). In addition, 15 proteins that were below the limit of detection 
(LOD), were not included in the analysis. The Olink® quality control samples are considered as 
“flagged” if they deviate more than 0.3 NPX from the median of all samples in one of two control 
assays for incubation and detection. The LOD is defined by the three negative controls run on each 
plate and set to three standard deviations above the measured background. Patients with missing or 
unusable samples (22 samples in the discovery phase and 74 samples in the replication phase) were 
not considered for the analyses. Where the assay results were partially missing i.e. results were 
missing for 1 or 2 of the 3 plates (83 patients in the discovery phase and 4 patients in the replication 
phase) then multiple imputation using chained equations was used21. 
The abbreviations, full names and respective Olink® multiplex panels of the studied proteins 
are described in the Supplemental Table 1. 
The assays were performed “blinded” to case/control status with cases and controls randomly 
distributed across plates. The proteomic results were then merged with the baseline data, which 
included the case-control status, matching variables and the clinical risk factors.  
Statistical and bioinformatics considerations 
For the baseline clinical characteristics, continuous variables are expressed as means and respective 
standard deviation (SD). Categorical variables are presented as frequencies and percentages. Patient 
baseline characteristics were compared between cases and controls using Chi2 tests for categorical 
variables and t-tests for continuous variables. 
The main aim of this study was to test multiple proteins with regards to their association with 
incident HF and the respective underlying mechanistic pathways. Logistic regression models 
adjusting for the matching variables (age, sex, cohort, follow-up time) were used to identify protein 
biomarkers associated with incident HF in the discovery and replication phases22 (Supplemental 
Table 2). Only those proteins which were found to be statistically significant (after correction for 
“false discoveries”) in the discovery phase (n=89) were taken forward for consideration in the 
replication phase. In both phases we corrected for multiple testing using a false discovery rate (FDR) 
of 1%23. Additional adjustment for the pre-specified clinical risk factors previously found to represent 
the best clinical prognostic model for incident HF in the HOMAGE population24 (smoking, diabetes, 
history of coronary artery disease, serum creatinine, body mass index, systolic blood pressure, use of 
antihypertensive medication, and heart rate) was also performed, providing similar results 
(Supplemental Table 3). Since proteins were measured using NPX (Normalized Protein eXpression) 
values on a log2 scale, the odds ratio for each protein estimates the increase in the odds of HF 
associated with a doubling in the protein concentration. After the identification of the “top” proteins, 
common to the derivation and replication phases, we performed a multivariable a stepwise forward 
model adjusted on age, sex, cohort, phase, follow-up time, smoking, diabetes, history of coronary 
artery disease, serum creatinine, body mass index, systolic blood pressure, use of antihypertensive 
medication, and heart rate forced into the model  with a p-value for inclusion set at 0.05. This set of 
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analyses was performed using STATA version 15 software (StataCorp. 2017. Stata Statistical 
Software: Release 15. College Station, TX: StataCorp LP).  
We used knowledge-based network analysis with induced network approach by 
consensuspathDB (CPDB) online server (accessed on 29 January 2019) from Max Planck Institute for 
Molecular Genetics to identify the links among the protein biomarkers selected in the previous step 
(discovery and replication with adjustment on the matching variables), based on known knowledge of 
interaction networks (protein interactions, genetic interactions, biochemical interactions, and gene 
regulatory interactions)11. The network analysis also identifies additional proteins (intermediate 
nodes) based on knowledge-based interactions (with exclusion of low-confidence interactions 
quantified by a z-score ≤20 calculated for each intermediate node). As a validation step, network 
analysis was repeated using ClueGO network analysis (version 2.5.3), using implemented biological 
GO processes25. Extra known connection between BNP (brain natriuretic peptide) and angiotensin 
was added to the network manually due to their well described interplay on blood pressure and hydro-
electrolytic regulation26, 27. The generated network was reorganized in Cytoscape (version 3.5) to 
merge genes with their expressed proteins and visualize the results. An additional overrepresentation 
analysis was performed using only the GO-biological processes and molecular function enriched by 
selected proteins against proteins on the OLINK panels, introducing an adjustment for the clustering 
of proteins on the network and consolidating the strength of true enrichment. 
 
Results 
Study population 
The baseline characteristics of the studied population for both discovery (IA) and replication phases 
(IB) is depicted in Table 1. Cases and controls were well matched for age, sex, cohort and follow-up 
time (i.e. the matching variables) in both phases. Cases had higher BMI, creatinine, were more often 
hypertensive (with anti-hypertensive medications), diabetic, and had more often coronary artery 
disease. All these variables were included in the HOMAGE prognostic model24 and were used for 
further adjustment in the models (please see below). 
Biomarkers associated with incident heart failure 
Of the 252 proteins studied, adjusting for the matching variables age, sex, and follow-up time, 89 
proteins were found to be associated with incident HF in the discovery phase, of which 38 were also 
associated with incident HF in the replication phase. Table 2. All 38 proteins were positively 
associated with incident HF, except for TWEAK (tumor necrosis factor ligand superfamily member 
12) and PON3 (paraoxonase), where patients with higher concentrations of these proteins were less 
likely to develop HF. Further adjusting for the clinical risk factors (smoking, diabetes, history of 
coronary artery disease, serum creatinine, body mass index, systolic blood pressure, use of 
antihypertensive medication, and heart rate) previously determined in the well calibrated HOMAGE 
clinical risk model24, provides similar associations to those presented in Table 2, suggesting that these 
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associations were independent of the patients` clinical risk (also supported by the weak correlation 
between the study proteins and the clinical risk factors). Supplemental Table 3 & 4.   
The multivariable stepwise model including the matching variables and the clinical risk 
factors forced into the model, plus the 38 proteins independently identified in both the discovery and 
replication phases, retained BNP, TWEAK, NTproBNP, REN, TRAILR2, PON3, CCL16, and 
SLAMF1 as the biomarkers with stronger association with incident HF. Supplemental Table 5.    
Induced network results 
The 38 incident HF-associated protein biomarkers were linked with each other by known protein 
interactions, biochemical interactions, and gene regulatory interactions (Figure 1), directly or via 
intermediate nodes (Supplemental Table 6). Our results pointed to 4 clusters with clearly defined 
functions: 1) inflammatory/apoptosis of mainly TNF-family members, 2) extracellular matrix 
remodelling, angiogenesis and cell growth, 3) a renin-angiotensin system associated with blood 
pressure regulation and one minor cluster including metabolic proteins, and 4) metabolism, associated 
with cholesterol and atherosclerosis. The two major clusters inflammatory/apoptosis and blood 
pressure regulation were also detected as the main groups using the ClueGO network analysis 
(Supplemental Figure 2). The TNF-family members, their representative pathways and blood 
pressure regulation remained significantly enriched after adjustment for the preselection of proteins 
(Supplemental Table 7).  
In addition, this analysis revealed multiple intracellular transcription factors: TP53 (tumor 
protein 53), HNF1B (hepatocyte nuclear factor-1-beta), HIF1A/ARNT (hypoxia inducible factor 
alfa/aryl hydrocarbon receptor nuclear translocator) and STAT6 (signal transducer and activator of 
transcription 6), which are not detected with our plasma protein panels. However, these transcription 
factors may supplement the biomarker profile of patients at high risk for incident HF, providing 
additional perspective on the interpretation of the pathophysiological processes driving HF. The role 
of each biomarker linked to the identified network clusters is furtherly detailed in the discussion 
section. 
 
Discussion 
In the present study we identified 38 plasma proteins associated with incident HF (in both the 
discovery and replication phases). The selected proteins allowed the identification of 4 main network 
clusters underpinning incident HF: 1) inflammation and apoptosis; 2) extracellular matrix 
remodelling, angiogenesis and growth; 3) blood pressure regulation, and 4) metabolism. These 
findings are original and provide important insight on the pathophysiological mechanisms leading to 
HF, potentially creating the basis for the development of new HF prevention strategies, personalized 
to each individual patient underlying mechanism. 
A recently published study10 investigated the longitudinal association between high-
throughput proteomics (also using OLINK® technology) and HF risk in two community-based 
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prospective cohorts of elderly individuals without HF at baseline. To some extent, the proteins 
identified in that study overlapped with ours. Specifically, TRAILR2 (trail receptor 2), GDF-15 
(growth differentiation factor 15), and MMP-12 (matrix metalloproteinase 12) were identified in both 
studies across all discovery steps. However, the study by Stenemo et al. studied 80 proteins, whereas 
ours analysed 252. Moreover, our study was aimed to identify the “biological signatures” leading to 
HF.  
Inflammation and apoptosis cluster 
Inflammation and apoptosis, as pointed by the expression of TNF-family members, may be an 
important pathway leading to HF that may be identified by the expression of circulation proteins such 
as TRAILR2, IL16 (interleukin 16), IL4RA (interleukin 4 receptor alfa), CD4 (T-cell surface 
glycoprotein CD4), TNFRSF10A (tumor necrosis factor receptor superfamily member 10A), 
TNFRSF11A (tumor necrosis factor receptor superfamily member 11A), TNFR1 (tumor necrosis 
factor receptor 1), TNFR2 (tumor necrosis factor receptor 2), TNFRSF13B (tumor necrosis factor 
receptor superfamily member 13B), TNFRSF14 (tumor necrosis factor receptor superfamily member 
14), CCL16 (C-C motif chemokine 16), SLAMF1 (signalling lymphocytic activation molecule family 
member 1), and TWEAK.  Elevated TNF signalling restrains cardiomyocyte differentiation of 
resident cardiac stem cells and enhance adrenergic activation, promoting adverse cardiac remodelling 
(also reflected by the elevated remodelling markers)28. The TRAILR2 protein (otherwise known as 
death receptor 5) is encoded by the TNFSF10 gene and is a receptor belonging to the TNF 
superfamily that preferentially induces apoptosis after binding of its ligand TRAIL29, 30. Increased 
levels of TRAILR2 have been associated with adverse cardiovascular events in patients with 
myocardial infarction, probably due to intensified apoptotic activity31. Interleukins, as “upstream” 
biomarkers of inflammation converge on the central TNF signalling pathway, having major influence 
on atherosclerosis, and consequently on the risk of cardiovascular disease32.  Another TNF 
superfamily member – TWEAK - activates the NF-κB (nuclear factor kappa B) and regulates several 
cell functions such as proliferation, migration, differentiation, cell death, inflammation, angiogenesis, 
and collagen synthesis of cardiac fibroblasts33,34, 35. Low TWEAK has been associated with increased 
risk of death in patients with overt HF36 and patients with HF and reduced ejection fraction had lower 
TWEAK levels compared to “controls”34. The TWEAK-induced proliferation of cardiomyocytes and 
its immunomodulatory effects may provide basis to these findings36. Apart from binding to its active 
receptor Fn14, TWEAK can also bind to a scavenger receptor CD163, which was shown to be 
upregulated in HF, explaining the decreased levels and activity of TWEAK in HF34.  
 The inflammation/apoptosis cluster grouped many proteins with strong and independent 
association with HF: TWEAK, TRAILR2, CCL16 and SLAMF1. 
Extracellular matrix remodelling, angiogenesis and growth cluster 
Another major pathway identified as leading to HF was, extracellular matrix remodelling, 
angiogenesis and growth supported by the expression of ADM (adrenomedullin), IGFBP7 (insulin-
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like growth factor-binding protein 7), PGF (placenta growth factor), PLC (perlecan), GAL9 (galectin 
9), MMP12 (matrix metalloproteinase 12), UPAR (urokinase plasminogen activator surface receptor), 
SLAMF1 (signalling lymphocytic activation molecule), CEACAM8 (carcinoembryonic antigen 
related cell adhesion molecule 8), GDF15 (growth differentiation factor 15), FGF23 (fibroblast 
growth factor 23), and OPN (osteopontin).  ADM is a vasodilator peptide predominantly produced by 
the vascular endothelium and smooth muscle that increases in response to hemodynamic stress37.  
IGFBP7 participates in the regulation of the availability of insulin growth factor in body fluids and 
tissues. IGFBP7 has been found to be associated with diastolic dysfunction and is also a strong 
prognosticator in HF38.  PGF is increased by pressure overload in the heart where it is expressed in 
both myocytes and other cells infiltrating the heart39. PLC is constituent of the extra-cellular matrix 
that regulates angiogenesis and cell autophagy40. PLC pro-angiogenic effects may be used for the 
treatment of ischemic diseases41. GAL9 is produced by the extracellular matrix and may be increased 
inpatients with ischemic stroke, its role in HF requires further study42. Matrix metalloproteinases 
degrade extracellular matrix proteins and play important roles in development and tissue repair. 
MMP-12 contributes to plaque growth and destabilization and increased levels of this proteins have 
been associated with higher atherosclerotic disease burden43. SLAMF1 is expressed in the surface of 
lymphocytes and is involved in the control of infectious and neoplastic processes44. CEACAM8 is 
released by granulocytes and is also involved in immune regulation45. The role of SLAMF1 and 
CEACAM8 in HF requires further investigation. However, they are both related to UPAR that 
induces cardiac fibrosis and macrophage accumulation, and is associated with worse prognosis in 
HF46, 47. GDF15 regulates inflammation and apoptosis, both key mechanisms in cardiac remodelling 
that are potentially associated with incident HF48, 49. FGF23 is released by the osteocytes and is 
essential for the regulation of the metabolism of phosphate, calcium and vitamin D. Importantly, 
FGF23 promotes myocardial fibrosis and has been associated with coronary heart disease and HF50, 51. 
OPN is a member of the extracellular matrix protein family. OPN expression increases under a variety 
of pathophysiological conditions affecting the heart and has been associated with increased incidence 
of cardiovascular diseases, including HF52.  
Blood pressure regulation cluster 
Another major pathway identified as leading to HF was associated with blood pressure regulation, 
supported by the increased expression of renin, angiotensin converting enzyme and BNP/NTproBNP. 
The renin-angiotensin-aldosterone (RAAS) and the natriuretic peptide systems have been thoroughly 
associated with cardiovascular disease, including hypertension and HF53. Natriuretic peptides (BNP 
and NTproBNP) are produced by the cardiomyocytes, endothelial cells, T cells, and macrophages 
infiltrating the heart in response to cardiac overload54. BNP/NTproBNP are recommended in the 
current guidelines for diagnostic and prognostic assessment in HF55, 56. Natriuretic peptides have been 
associated with incident HF57 and a natriuretic peptide-based strategies for preventing HF have 
reduced the rates of both systolic and diastolic dysfunction58. The RAAS and BNP are closely related 
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by inhibition on to each other by having counterbalanced regulatory functions on blood pressure26. 
Moreover, angiotensin can upregulate cardiac BNP gene expression27 . Enhanced RAAS under high 
BNP may reflect a dysregulation on blood pressure leading to HF development. Natriuretic peptides 
and renin were strongly and independently associated with incident HF.  
Metabolism cluster 
The other pathway identified as leading to HF was associated with metabolism, supported by the 
identification of PON3, FABP4 (fatty acid binding protein 4), and RARRES2 (retinoic acid receptor 
responder protein 2). PON3 has been associated with HDL increase and with the inhibition of LDL 
oxidation, thus PON3 expression might be protective in the cardiovascular setting59. In our study 
PON3 was negatively associated with incident HF risk, suggesting that anti-oxidation may play a role 
in the mechanisms associated with HF development. In line with TWEAK, preclinical evidence 
supports a cardioprotective role for PON3 (which was also independently associated with incident HF 
in the multivariable model). FABP4 is predominantly expressed in macrophages and adipose tissue 
where it regulates fatty acids storage and lipolysis; FABP4 is also an important mediator of 
inflammation that has been associated with higher risk of cardiovascular events60, 61. RARRES2 (or 
chemerin) is an adipose-derived signalling molecule that regulates adipogenesis and adipocyte 
metabolism, and it has also been associated with higher risk of cardiovascular events62, 63. 
Overall, the results of our proteomic biomarker assessments in patients at risk of developing 
HF suggest that progression towards HF is likely to involve the interplay of several 
pathophysiological mechanisms, such as “heart stress”, blood pressure regulation, apoptosis, 
inflammation and metabolism-related mechanisms. A previous report identified cytokine response, 
extracellular matrix organization, and inflammation as major pathways underlining HF with preserved 
ejection fraction64. The next step of this important data is to determine the activity of these processes 
in different HF stages and eventually per individual. This will provide the basis for further 
development strategies in preventing HF and focusing on these specific pathways at early stages of 
the disease for an individual treatment approach. The intracellular transcription factors TP53, HNF1B, 
HIF1A/ARNT and STAT6, which are not measured in our plasma protein panels, may complement 
the biomarker profile of patients at high risk for incident HF65, suggesting a combined multi-OMICS 
approach currently being investigated within the HOMAGE consortium.  
 
Limitations 
Several limitations should be highlighted in the present study. First, this is an observational case-
control study, hence causality cannot be ascertained. The bioinformatics approach also does not allow 
causality assessment, but allow for the generation of hypothesis on the underlying pathways 
associated with this proteomic expression. Also, we must be aware of the biases and 
oversimplification in network topology. For example, most network databases are overrepresented by 
well-studied proteins and their interactions. This will lead to overrepresentation of these interactions 
13 
 
in the analysis as there are more interactions known for these proteins66. Second, incident HF was 
defined as first HF hospitalization, which does not exclude patients that might already have HF but 
without previous hospitalizations. Also, for the avoidance of competing risk, we excluded patients 
who died during follow up. Therefore, it is possible that we missed patients where death was the first 
(and last) manifestation of HF. Third, we did not have access to the reported ejection fraction at the 
time of hospitalization, therefore we cannot assess the potential value of these biomarkers in 
distinguishing progression to HF with reduced ejection fraction from HF with preserved ejection 
fraction and/or the HF cause. Fourth, clinical detail (signs, symptoms, ECG and other complementary 
exams), troponin and natriuretic peptides at the time of hospitalization are not available in the dataset. 
This information would help in further phenotyping these patients, and in differentiating the cases 
from the controls. Fifth, the proteomics assay does not provide standard concentration units, making 
comparisons with clinically applied cut-offs difficult, however the Olink® standard procedures 
reassure a good correlation with the “standard” measurement methodologies. In addition, we did not 
use large unbiased screens but rather selected protein biomarkers based on mechanistic hypotheses. 
The 3 studied Olink® panels (CVD II, III, and Inflammation) contain circulating proteins previously 
found to be associated with cardiovascular and/or inflammatory diseases. Many other “pathways” are 
missing (for example, metabolism(omics), that could enrich our networks Therefore, we cannot 
exclude the role of other mechanisms not targeted with our proteomics screen. Finally, prospective 
validation of these biomarkers in other populations is required to improve the external validation of 
these results. 
 
Conclusions 
After adjustment for the matching variables age, sex, follow-up time and correction for multiplicity of 
tests we identified 38 proteins in two independent sets associated with incident HF. Cluster of the 
selected proteins allowed the identification of 4 main networks leading to HF: 1) inflammation and 
apoptosis; 2) extracellular matrix remodelling, angiogenesis and growth; 3) blood pressure regulation; 
and 4) metabolism. These findings provide important insight on the pathophysiological mechanisms 
leading to HF. 
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What is new? 
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We present a nested case:control study (with derivation and replication cohorts) to study 252 
circulation proteins and their association with new-onset heart failure, to assess the mechanistic 
pathways that may lead to the development of heart failure.  
What are the clinical implications? 
We identified four main networks that may lead to heart failure. These include inflammation and 
apoptosis; extracellular matrix remodelling, angiogenesis and growth; blood pressure regulation; and 
metabolism. These findings provide important insight on the mechanisms leading to heart failure and 
may help in the development of future “personalized” therapies. 
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Figure 1. Induced network analysis: protein interactions, biochemical interactions, and 
gene regulatory interactions 
 
Legend: Please see the supplemental table 4 for the full names of the biomarkers and 
intermediates. 
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Table 1. Characteristics of the study population for both discovery and replication phases 
Characteristics 
Discovery 
 
Replication 
 Cases Controls 
p-value 
 Cases Controls 
p-value 
 N=286 N=591  N=276 N=280 
Age-years 74.4 (3.5) 74.4 (3.5) 0.94  75.1 (3.5) 75.2 (3.6) 0.81 
Male sex-Nos.(%) 154 (53.8) 320 (54.1) 0.93  157 (56.9) 158 (56.4) 0.91 
Cohort-Nos.(%)     0.74      0.57 
  HABC 215 (75.2) 433 (73.3)   109 (39.5) 99 (35.4)  
  Predictor 15 (5.2) 29 (4.9)   29 (10.5) 29 (10.4)  
  Prosper 56 (19.6) 129 (21.8)   138 (50.0) 152 (54.3)  
Smoking Status-Nos.(%)     0.29      0.50 
  Never 139 (48.6) 309 (52.5)   157 (56.9) 169 (60.4)  
  Current 30 (10.5) 71 (12.1)   57 (20.7) 47 (16.8)  
  Past 117 (40.9) 209 (35.5)   62 (22.5) 64 (22.9)  
Body Mass Index-kg/m2 28.1 (4.8) 27.0 (4.4) <0.001  27.6 (4.7) 26.7 (4.2) 0.02 
Systolic blood pressure-
mmHg 
142.4 (23.4) 141.2 (23.0) 0.48  148.2 (22.9) 145.9 (22.7) 0.25 
Diastolic blood pressure-
mmHg 
75.2 (13.7) 74.6 (12.1) 0.45  78.5 (13.7) 78.2 (12.6) 0.76 
Heart rate-bpm 67 (11.8) 64  (11.1) 0.004  68 (11.9) 66 (10.9) 0.09 
Serum Creatinine-µmol/l 98.8 (27.7) 93.5 (21.3) 0.002  102.8 (28.2) 95.5 (21.5) <0.001 
Total cholesterol-mmol/l 5.33 (1.00) 5.31 (0.99) 0.88  5.34 (0.97) 5.49 (0.95) 0.08 
HDL-cholesterol-mmol/l 1.28 (0.39) 1.34 (0.41) 0.04  1.29 (0.37) 1.36 (0.42) 0.02 
LDL-cholesterol-mmol/l 3.32 (0.89) 3.29 (0.92) 0.64  3.41 (0.91) 3.48 (0.85) 0.35 
Triglycerides-mmol/l 1.61 (0.83) 1.55 (0.96) 0.33  1.53 (0.77) 1.45 (0.66) 0.19 
Blood glucose-mmol/l 5.99 (2.18) 5.60 (1.56) 0.002  5.92 (1.99) 5.49 (1.34) 0.003 
Comorbidities-Nos.(%)            
  Hypertension 219 (76.8) 408 (69.2) 0.02  184 (66.9) 177 (63.4) 0.39 
  Diabetes 55 (19.2) 68 (11.5) 0.002  49 (17.8) 32 (11.4) 0.03 
  CVD 124 (44.4) 168 (28.9) <0.001  149 (54.0) 105 (37.5) <0.001 
  CAD 103 (36.5) 126 (21.6) <0.001  114 (41.3) 78 (27.9) <0.001 
  PAD 14 (5.0) 22 (3.8) 0.40  14 (5.1) 4 (1.4) 0.01 
  Cerebrovascular disease 25 (8.9) 49 (8.3) 0.76  34 (12.3) 25 (8.9) 0.19 
Medications-Nos.(%)            
  Anti-hypertensives 192 (67.1) 318 (54.0) <0.001  198 (71.7) 174 (62.1) 0.02 
  ACEi 64 (22.4) 74 (12.6) <0.001  63 (22.8) 47 (16.8) 0.07 
  CCB 86 (30.1) 114 (19.4) <0.001  77 (27.9) 53 (18.9) 0.01 
  Diuretics 88 (30.8) 141 (23.9) 0.03  102 (37.0) 89 (31.8) 0.20 
  Beta-blockers 51 (17.8) 97 (16.5) 0.61  62 (22.5) 54 (19.3) 0.36 
  ARBs 13 (4.5) 14 (2.4) 0.08  17 (6.2) 13 (4.6) 0.43 
  Antiplatelet 128 (44.8) 228 (38.7) 0.09  126 (45.7) 102 (36.4) 0.03 
Numbers are mean (SD) unless otherwise specified 
Legend: CVD, cardiovascular diseases; CAD, coronary artery diseases; PAD, peripheral arterial diseases; ACEi, angiotensin converting 
enzyme inhibitors; CCB,  calcium channel blockers, ARBs, angiotensin receptors blockers. 
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Table 2. Odds ratios (OR) and 95% confidence intervals (CI) for the selected proteins with regards to their association with 
incident heart failure after adjustment for the matching variables and correction for multiple comparisons in both discovery 
and replication sets 
 Protein name Discovery Replication 
 OR (95% CI) P-value OR (95% CI) P-value 
BNP 1.62 (1.42, 1.86) <0.0001 1.73 (1.50, 2.01) <0.0001 
NTPROBNP 1.74 (1.46, 2.06) <0.0001 2.00 (1.64, 2.44) <0.0001 
TRAILR2 3.26 (2.32, 4.60) <0.0001 3.22 (2.21, 4.69) <0.0001 
TNFRSF13B 1.74 (1.34, 2.24) <0.0001 2.61 (1.82, 3.74) <0.0001 
GAL9 2.96 (1.95, 4.49) <0.0001 3.14 (2.01, 4.91) <0.0001 
FGF23 1.70 (1.40, 2.07) <0.0001 1.84 (1.44, 2.36) <0.0001 
TNFRSF10A 2.63 (1.88, 3.69) <0.0001 2.56 (1.74, 3.77) <0.0001 
REN 1.31 (1.11, 1.55) 0.0018 1.54 (1.29, 1.85) <0.0001 
TNFRSF11A 2.09 (1.61, 2.72) <0.0001 1.95 (1.47, 2.59) <0.0001 
GDF15 2.74 (2.08, 3.61) <0.0001 1.89 (1.44, 2.47) <0.0001 
FABP4 1.82 (1.51, 2.19) <0.0001 1.57 (1.29, 1.92) <0.0001 
SLAMF7 1.55 (1.26, 1.91) <0.0001 2.16 (1.52, 3.06) <0.0001 
CCL16 1.47 (1.21, 1.79) <0.0001 1.72 (1.34, 2.22) <0.0001 
TWEAK 0.51 (0.36, 0.73) 0.0003 0.53 (0.39, 0.71) <0.0001 
KIM1 1.41 (1.19, 1.68) <0.0001 1.51 (1.23, 1.84) <0.0001 
CD4 2.06 (1.49, 2.85) <0.0001 2.17 (1.49, 3.16) <0.0001 
VSIG2 1.43 (1.14, 1.81) 0.0025 1.76 (1.33, 2.32) <0.0001 
PON3 0.71 (0.58, 0.87) 0.0011 0.64 (0.51, 0.80) <0.0001 
PLGF 2.17 (1.54, 3.06) <0.0001 1.95 (1.38, 2.75) 0.0002 
MMP12 1.64 (1.32, 2.03) <0.0001 1.54 (1.23, 1.92) 0.0002 
ADM 2.56 (1.82, 3.59) <0.0001 1.80 (1.32, 2.45) 0.0002 
RARRES2 3.33 (2.02, 5.51) <0.0001 2.05 (1.38, 3.05) 0.0004 
CEACAM8 1.51 (1.22, 1.86) 0.0001 1.49 (1.19, 1.86) 0.0005 
SLAMF1 1.44 (1.17, 1.76) 0.0005 1.62 (1.23, 2.13) 0.0005 
TNFR1 2.40 (1.75, 3.28) <0.0001 1.63 (1.23, 2.16) 0.0007 
AGRP 1.82 (1.38, 2.40) <0.0001 1.90 (1.31, 2.76) 0.0007 
TNFR2 2.11 (1.58, 2.82) <0.0001 1.55 (1.20, 2.00) 0.0008 
IGFBP7 1.66 (1.24, 2.23) 0.0006 1.60 (1.21, 2.11) 0.0010 
UPAR 2.70 (1.94, 3.75) <0.0001 1.67 (1.23, 2.28) 0.0011 
PAR1 1.86 (1.33, 2.60) 0.0003 1.74 (1.24, 2.45) 0.0014 
PLC 2.26 (1.59, 3.21) <0.0001 1.76 (1.24, 2.49) 0.0015 
ACE2 1.60 (1.27, 2.02) <0.0001 1.52 (1.17, 1.98) 0.0016 
IL16 1.54 (1.20, 1.97) 0.0007 1.46 (1.15, 1.86) 0.0019 
TFF3 1.61 (1.32, 1.95) <0.0001 1.45 (1.15, 1.84) 0.0019 
OPN 2.00 (1.52, 2.63) <0.0001 1.50 (1.16, 1.95) 0.0021 
SPON2 2.86 (1.50, 5.48) 0.0015 2.40 (1.36, 4.25) 0.0026 
IL4RA 1.52 (1.15, 2.02) 0.0033 1.62 (1.18, 2.22) 0.0029 
TNFRSF14 2.09 (1.55, 2.82) <0.0001 1.52 (1.15, 2.01) 0.0034 
Legend: BNP, brain natriuretic peptide; NTPROBNP, N-terminal prohormone brain natriuretic peptide; TRAILR2, TNF-related apoptosis-
inducing ligand receptor 2; TNFRSF13B, tumor necrosis factor receptor superfamily member 13B; GAL9, galectin-9; FGF23, fibroblast 
growth factor 23; TNFRSF10A, tumor necrosis factor receptor superfamily member 10A, REN, renin; TNFRSF11A, tumor necrosis factor 
receptor superfamily member 11A; GDF15, growth/differentiation factor 15; FABP4, fatty acid-binding protein; SLAMF7, SLAM family 
member 7; CCL16, C-C motif chemokine 16; TWEAK, tumor necrosis factor (Ligand) superfamily, member 12; KIM1, kidney injury 
molecule 1; CD4, T-cell surface glycoprotein CD4; VSIG2, v-set and immunoglobulin domain-containing protein 2; PON3, paraoxonase; 
PLGF, placenta growth factor; MMP12, matrix metalloproteinase-12; ADM, adrenomedullin; RARRES2, retinoic acid receptor responder 
protein 2; CEACAM8, carcinoembryonic antigenrelated cell adhesion molecule 8; SLAMF1, signaling lymphocytic activation molecule; 
tnfr1, tumor necrosis factor receptor 1; AGRP, agouti-related protein; TNFR2, tumor necrosis factor receptor 2; IGFBP7, insulin-like growth 
factor-binding protein 7; UPAR, urokinase plasminogen activator surface receptor; PAR1, proteinase-activated receptor 1; PLC, perlecan; 
ACE2, angiotensin-converting enzyme 2; IL16, pro-interleukin-16; TFF3, trefoil factor 3; OPN, osteopontin; SPON2, spondin-2; IL4RA, 
interleukin-4 receptor subunit alpha; TNFRSF14, tumor necrosis factor receptor superfamily member 14. 
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Supplemental Table 1. Protein names and respective Olink® panel sorted in alphabetical order 
Protein full name 
Entry name Olink® 
Panel* 
Uniprot 
ID** 
Angiotensin-converting enzyme 2 ACE2 CVD II Q9BYF1 
Adenosine Deaminase ADA INF P00813 
Adisintegrin and metalloproteinase with thrombospondin 
motifs 13 
ADAMTS13 CVD II 
Q76LX8 
ADM ADM CVD II P35318 
Agouti-related protein AGRP CVD II O00253 
CD166 antigen ALCAM CVD III Q13740 
Protein AMBP AMBP CVD II P02760 
Angiopoietin-1 ANG1 CVD II Q15389 
Aminopeptidase N APN CVD III P15144 
Axin-1 AXIN1 INF O15169 
Tyrosine-protein kinase receptor UFO AXL CVD III P30530 
Azurocidin AZU1 CVD III P20160 
Brain-derived neurotrophic factor BDNF INF P23560 
Beta-nerve growth factor BETANGF INF P01138 
Bleomycin hydrolase 
BLMHYDROL
ASE 
CVD III 
Q13867 
Bone morphogenetic protein 6 BMP6 CVD II P22004 
Natriuretic peptides B BNP CVD II P16860 
Eukaryotic translation initiation factor 4E-binding 
protein 1 
BP1_4E INF 
Q13541 
Carbonic anhydrase 5A, mitochondrial CA5A CVD II P35218 
Caspase-3 CASP3 CVD III P42574 
Caspase 8 CASP8 INF Q14790 
Eotaxin-1 CCL11 INF P51671 
C-C motif chemokine 15 CCL15 CVD III Q16663 
C-C motif chemokine 16 CCL16 CVD III O15467 
C-C motif chemokine 17 CCL17 CVD II Q92583 
C-C motif chemokine 19 CCL19 INF Q99731 
C-C motif chemokine 20 CCL20 INF P78556 
C-C motif chemikine 22 CCL22 CVD III O00626 
C-C motif chemokine 23 CCL23 INF P55773 
C-C motif chemokine 24 CCL24 CVD III O00175 
C-C motif chemokine 25 CCL25 INF O15444 
C-C motif chemokine 28 CCL28 INF Q9NRJ3 
C-C motif chemokine 3 CCL3 CVD II P10147 
C-C motif chemokine 4 CCL4 INF P13236 
Scavenger receptor cysteine-rich type 1 protein M130 CD163 CVD III Q86VB7 
Natural killer cell receptor 2B4 CD244 INF Q9BZW8 
T-cell surface glycoprotein CD4 CD4 CVD II P01730 
CD40L receptor CD40 INF P25942 
CD40 ligand CD40L CVD II P29965 
T-cell surface glycoprotein CD5 CD5 INF P06127 
T cell surface glycoprotein CD6 CD6 INF P30203 
SLAM family member 5 CD84 CVD II Q9UIB8 
Complement component C1q receptor CD93 CVD III Q9NPY3 
CUB domain-containing protein 1 CDCP1 INF Q9H5V8 
Cadherin-5 CDH5 CVD III P33151 
Carcinoembryonic antigenrelated cell adhesion molecule 
8 
CEACAM8 CVD II 
P31997 
Chitinase-3-like protein 1 CHI3L1 CVD III P36222 
Chitotriosidase-1 CHIT1 CVD III Q13231 
Contactin-1 CNTN1 CVD III Q12860 
Collagen alpha-1(I) chain COL1A1 CVD III P02452 
Carboxypeptidase A1 CPA1 CVD III P15085 
Carboxypeptidase B CPB1 CVD III P15086 
Macrophage colony-stimulating factor 1 CSF1 INF P09603 
Cystatin D CST5 INF P28325 
Cystatin-B CSTB CVD III P04080 
Chymotrypsin C CTRC CVD II Q99895 
Cathepsin D CTSD CVD III P07339 
Cathepsin L1 CTSL1 CVD II P07711 
Cathepsin Z CTSZ CVD III Q9UBR2 
Fractalkine CX3CL1 INF P78423 
C-X-C motif chemokine 1 (CVD2) CXCL1 CVD II P09341 
C-X-C motif chemokine 10 CXCL10 INF P02778 
C-X-C motif chemokine 11 CXCL11 INF O14625 
C-X-C motif chemokine 16 CXCL16 CVD III Q9H2A7 
C-X-C motif chemokine 5 CXCL5 INF P42830 
C-X-C motif chemokine 6 CXCL6 INF P80162 
C-X-C motif chemokine 9 CXCL9 INF Q07325 
Decorin DCN CVD II P07585 
2,4-dienoyl-CoA reductase, mitochondrial DECR1 CVD II Q16698 
Dickkopf-related protein 1 DKK1 CVD II O94907 
Azurocidin DLK1 CVD III P80370 
Delta and Notch-like epidermal growth factor-related 
receptor 
DNER INF 
Q8NFT8 
Epidermal growth factor receptor EGFR CVD III P00533 
Protein S100-A12 ENRAGE INF P80511 
Epithelial cell adhesion molecule EPCAM CVD III P16422 
Ephrin type-B receptor 4 EPHB4 CVD III P54760 
Fatty acid-binding protein, intestinal FABP2 CVD II P12104 
Fatty acid-binding protein, adipocyte FABP4 CVD III P15090 
Tumor necrosis factor receptor superfamily member 6 FAS CVD III P25445 
Fibroblast growth factor 19 FGF19 INF O95750 
Fibroblast growth factor 21 (CVD2) FGF21 CVD II Q9NSA1 
Fibroblast growth factor 23 (CVD2) FGF23 CVD II Q9GZV9 
Fibroblast growth factor 5 FGF5 INF P12034 
Fms-related tyrosine kinase 3 ligand FLT3L INF P49771 
Follistatin FS CVD II P19883 
Galectin-3 GAL3 CVD III P17931 
Galectin-4 GAL4 CVD III P56470 
Galectin-9 GAL9 CVD II O00182 
Growth/differentiation factor 15 GDF15 CVD III Q99988 
Growth/differentiation factor 2 GDF2 CVD II Q9UK05 
Growth hormone GH CVD II P01241 
Gastric intrinsic factor GIF CVD II P27352 
Lactoylglutathione lyase GLO1 CVD II Q04760 
Granulins GRN CVD III P28799 
Gastrotropin GT CVD II P51161 
Hydroxyacid oxidase 1 HAOX1 CVD II Q9UJM8 
Proheparin-binding EGF-like growth factor HBEGF CVD II Q99075 
Glial cell line-derived neurotrophic factor HGDNF INF P39905 
Hepatocyte growth factor HGF INF P14210 
Heme oxygenase 1 HO1 CVD II P09601 
Osteoclast-associated immunoglobulin-like receptor HOSCAR CVD II Q8IYS5 
Heat shock 27 kDa protein HSP27 CVD II P04792 
Intercellular adhesion molecule 2 ICAM2 CVD III P13598 
Alpha-L-iduronidase IDUA CVD II P35475 
Insulin-like growth factor-binding protein 1 IGFBP1 CVD III P08833 
Insulin-like Growth Factor-Binding Protein 2 IGFBP2 CVD III P18065 
Insulin-like growth factor-binding protein 7 IGFBP7 CVD III Q16270 
Low affinity immunoglobulin gamma Fc region receptor 
II-b 
IGGFCRECEP
TORIIB 
CVD II 
P31994 
Interleukin-10 IL10 INF P22301 
Interleukin-10 receptor subunit alpha IL10RA INF Q13651 
Interleukin-10 receptor subunit beta IL10RB INF Q08334 
Interleukin-12 subunit beta IL12B INF P29460 
Interleukin-13 IL13 INF P35225 
Interleukin-15 receptor subunit alpha IL15RA INF Q13261 
Pro-interleukin-16 IL16 CVD II Q14005 
Interleukin-17A IL17A INF Q16552 
Interleukin-17C IL17C INF Q9P0M4 
Interleukin-17D IL17D CVD II Q8TAD2 
Interleukin-17 receptor A IL17RA CVD III Q96F46 
Interleukin-18 (CVD2) IL18 CVD II Q14116 
Interleukin-18-binding protein IL18BP CVD III O95998 
Interleukin-18 receptor 1 IL18R1 INF Q13478 
Interleukin-1 receptor antagonist protein IL1RA CVD II P18510 
Interleukin-1 receptor-like 2 IL1RL2 CVD II Q9HB29 
Interleukin-1 receptor type 1 IL1RT1 CVD III P14778 
Interleukin-1 receptor type 2 IL1RT2 CVD III P27930 
Interleukin-20 receptor subunit alpha IL20RA INF Q9UHF4 
Interleukin-27 IL27 CVD II Q8NEV9 
Interleukin-2 receptor subunit alpha IL2RA CVD III P01589 
Interleukin-4 receptor subunit alpha IL4RA CVD II P24394 
Interleukin-6 (CVD2) IL6 CVD II P05231 
Interleukin-6 receptor subunit alpha IL6RA CVD III P08887 
Interleukin-7 IL7 INF P13232 
Interleukin-8 IL8 INF P10145 
Melusin ITGB1BP2 CVD II Q9UKP3 
Integrin beta-2 ITGB2 CVD III P05107 
Junctional adhesion molecule A JAMA CVD III Q9Y624 
Kidney injury molecule 1 KIM1 CVD II Q96D42 
Kallikrein-6 KLK6 CVD III Q92876 
Latency-associated peptide transforming growth factor 
beta 1 
LAPTGFBETA
1 
INF 
P01137 
Low-density lipoprotein receptor 
LDLRECEPTO
R 
CVD III 
P01130 
Leptin LEP CVD II P41159 
Leukemia inhibitory factor receptor LIFR INF P42702 
Lectin-like oxidized LDL receptor 1 LOX1 CVD II P78380 
Lipoprotein lipase LPL CVD II P06858 
Lymphotoxin-beta receptor LTBR CVD III P36941 
Macrophage receptor MARCO MARCO CVD II Q9UEW3 
Myoglobin MB CVD III P02144 
Monocyte chemotactic protein 1 MCP1_CVD3 CVD III P13500 
Monocyte chemotactic protein 2 MCP2 INF P80075 
Monocyte chemotactic protein 3 MCP3 INF P80098 
Monocyte chemotactic protein 4 MCP4 INF Q99616 
Matrix extracellular phosphoglycoprotein MEPE CVD III Q9NQ76 
Tyrosine-protein kinase Mer MERTK CVD II Q12866 
Matrix metalloproteinase-1 MMP1 INF P03956 
Matrix metalloproteinase-10 MMP10 INF P09238 
Matrix metalloproteinase-12 MMP12 CVD II P39900 
Matrix metalloproteinase-2 MMP2 CVD III P08253 
Matrix metalloproteinase-3 MMP3 CVD III P08254 
Matrix metalloproteinase-7 MMP7 CVD II P09237 
Matrix metalloproteinase-9 MMP9 CVD III P14780 
Myeloperoxidase MPO CVD III P05164 
NF-kappa-B essential modulator NEMO CVD II Q9Y6K9 
Neurogenic locus notch homolog protein 3 NOTCH3 CVD III Q9UM47 
Neurotrophin-3 NT3 INF P20783 
N-terminal prohormone brain natriuretic peptide NTPROBNP CVDII P16860 
Osteoprotegerin OPG_CVD3 CVD III O00300 
Osteopontin OPN CVD III P10451 
Oncostatin-M OSM INF P13725 
Plasminogen activator inhibitor 1 PAI CVD III P05121 
Pappalysin-1 PAPPA CVD II Q13219 
Proteinase-activated receptor 1 PAR1 CVD II P25116 
Poly [ADP-ribose] polymerase 1 PARP1 CVD II P09874 
Proprotein convertase subtilisin/kexin type 9 PCSK9 CVD III Q8NBP7 
Platelet-derived growth factor subunit A 
PDGFSUBUNI
TA 
CVD III 
P04085 
Platelet-derived growth factor subunit B 
PDGFSUBUNI
TB 
CVD II 
P01127 
Programmed cell death 1 ligand 1 PDL1 INF Q9NZQ7 
Programmed cell death 1 ligand 2 PDL2 CVD II Q9BQ51 
Platelet endothelial cell adhesion molecule PECAM1 CVD III P16284 
Peptidoglycan recognition protein 1 PGLYRP1 CVD III O75594 
Elafin PI3 CVD III P19957 
Polymeric immunoglobulin receptor PIGR CVD II P01833 
Perlecan PLC CVD III P98160 
Placenta growth factor PLGF CVD II P49763 
Paraoxonase (PON 3) PON3 CVD III Q15166 
Prolargin PRELP CVD II P51888 
Brother of CDO PROTEINBOC CVD II Q9BWV1 
Serine protease 27 PRSS27 CVD II Q9BQR3 
Prostasin PRSS8 CVD II Q16651 
Myeloblastin PRTN3 CVD III P24158 
P-selectin glycoprotein ligand 1 PSGL1 CVD II Q14242 
Pulmonary surfactant-associated protein D PSPD CVD III P35247 
Pentraxin-related protein PTX3 PTX3 CVD II P26022 
Receptor for advanced glycosylation end products RAGE CVD II Q15109 
Retinoic acid receptor responder protein 2 RARRES2 CVD III Q99969 
Renin REN CVD II P00797 
Resistin RETN CVD III Q9HD89 
Stem cell factor (CVD2) SCF CVD II P21583 
Secretoglobin family 3A member 2 SCGB3A2 CVD III Q96PL1 
E-selectin SELE CVD III P16581 
P-selectin SELP CVD III P16109 
Serpin A12 SERPINA12 CVD II Q8IW75 
Tyrosine-protein phosphatase non-receptor type substrate 
1 
SHPS1 CVD III 
P78324 
SIR2-like protein 2 SIRT2 INF Q8IXJ6 
Signaling lymphocytic activation molecule SLAMF1 INF Q13291 
SLAM family member 7 SLAMF7 CVD II Q9NQ25 
Superoxide dismutase [Mn], mitochondrial SOD2 CVD II P04179 
Sortilin SORT1 CVD II Q99523 
Spondin-1 SPON1 CVD III Q9HCB6 
Spondin-2 SPON2 CVD II Q9BUD6 
Proto-oncogene tyrosine-protein kinase Src SRC CVD II P12931 
Sulfotransferase 1A1 ST1A1 INF P50225 
ST2 protein ST2 CVD III Q01638 
STAM-binding protein STAMPB INF O95630 
Serine/threonine-protein kinase 4 STK4 CVD II Q13043 
Tissue factor TF CVD II P13726 
Trefoil factor 3 TFF3 CVD III Q07654 
Tissue factor pathway inhibitor TFPI CVD III P10646 
Transforming growth factor alpha TGFALPHA INF P01135 
Protein-glutamine gamma-glutamyltransferase 2 TGM2 CVD II P21980 
Thrombospondin-2 THBS2 CVD II P35442 
Thrombopoietin THPO CVD II P40225 
Angiopoietin-1 receptor TIE2 CVD II Q02763 
Metalloproteinase inhibitor 4 TIMP4 CVD III Q99727 
Trem-like transcript 2 protein TLT2 CVD III Q5T2D2 
Thrombomodulin TM CVD II P07204 
Tumor necrosis factor TNF INF P01375 
TNF-beta TNFB INF P01374 
Tumor necrosis factor receptor 1 TNFR1 CVD III P19438 
Tumor necrosis factor receptor 2 TNFR2 CVD III P20333 
Tumor necrosis factor receptor superfamily member 10A TNFRSF10A CVD II O00220 
Tumor necrosis factor receptor superfamily member 10C TNFRSF10C CVD III O14798 
Tumor necrosis factor receptor superfamily member 11A TNFRSF11A CVD II Q9Y6Q6 
Tumor necrosis factor receptor superfamily member 13B TNFRSF13B CVD II O14836 
Tumor necrosis factor receptor superfamily member 14 TNFRSF14 CVD III Q92956 
Tumor necrosis factor receptor superfamily member 9 TNFRSF9 INF Q07011 
Tumor necrosis factor ligand superfamily member 13B TNFSF13B CVD III Q9Y275 
Tumor necrosis factor ligand superfamily member 14 TNFSF14 INF O43557 
Tissue-type plasminogen activator TPA CVD III P00750 
Transferrin receptor protein 1 TR CVD III P02786 
TNF-related apoptosis-inducing ligand TRAIL INF P50591 
TNF-related apoptosis-inducing ligand receptor 2 TRAILR2 CVD II O14763 
TNF-related activation-induced cytokine TRANCE INF O14788 
Tartrate-resistant acid phosphatase type 5 TRAP CVD III P13686 
Tumor necrosis factor (Ligand) superfamily, member 12 TWEAK INF O43508 
Urokinase-type plasminogen activator UPA_CVD3 CVD III P00749 
Urokinase plasminogen activator surface receptor UPAR CVD III Q03405 
Vascular endothelial growth factor A VEGFA INF P15692 
Vascular endothelial growth factor D VEGFD CVD II O43915 
V-set and immunoglobulin domain-containing protein 2 VSIG2 CVD II Q96IQ7 
von Willebrand factor VWF CVD III P04275 
Lymphotactin XCL1 CVD II P47992 
Legend: *CVII: cardiovascular II; CVIII: cardiovascular III; INF: inflammation panels; **UniProt ID 
from UniProt Knowledgebase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 2. Study proteins order by p-value (from lowest to highest in the discovery set) in 
both discovery and replication phases 
Protein name 
Discovery (phase 1a) Replication (phase 1b) 
Adjusted for matching variables Adjusted for matching variables and risk factors Adjusted for matching variables 
Adjusted for matching variables and 
risk factors 
OR (95% CI) P-value Z OR (95% CI) P-value Z OR (95% CI) P-value Z OR (95% CI) P-value Z 
NTPROBNP 1.74 (1.46, 2.06) <0.0001 6.3 1.79 (1.49, 2.14) <0.0001 6.3 2 (1.64, 2.44) <0.0001 6.9 2.06 (1.66, 2.54) <0.0001 6.6 
BNP 1.62 (1.42, 1.86) <0.0001 7 1.59 (1.37, 1.84) <0.0001 6.3 1.73 (1.50, 2.01) <0.0001 7.3 1.77 (1.51, 2.07) <0.0001 7.1 
GDF15 2.74 (2.08, 3.61) <0.0001 7.2 2.34 (1.72, 3.19) <0.0001 5.4 1.89 (1.44, 2.47) <0.0001 4.6 1.55 (1.15, 2.09) 0.0036 2.9 
TRAILR2 3.26 (2.32, 4.60) <0.0001 6.8 2.7 (1.86, 3.92) <0.0001 5.2 3.22 (2.21, 4.69) <0.0001 6.1 2.65 (1.72, 4.07) <0.0001 4.4 
CSTB 2.1 (1.67, 2.66) <0.0001 6.2 1.84 (1.43, 2.37) <0.0001 4.8 1.3 (1.07, 1.60) 0.0101 2.6 1.16 (0.93, 1.44) 0.1808 1.3 
UPAR 2.7 (1.94, 3.75) <0.0001 5.9 2.27 (1.61, 3.21) <0.0001 4.6 1.67 (1.23, 2.28) 0.0011 3.3 1.38 (1.00, 1.92) 0.0519 1.9 
VEGFA 2.65 (1.91, 3.67) <0.0001 5.9 2.27 (1.59, 3.22) <0.0001 4.5 1.52 (1.09, 2.11) 0.0129 2.5 1.27 (0.89, 1.80) 0.1837 1.3 
HGF 2.49 (1.78, 3.48) <0.0001 5.3 2.12 (1.50, 3.01) <0.0001 4.2 1.5 (1.11, 2.02) 0.0077 2.7 1.29 (0.94, 1.77) 0.119 1.6 
CXCL9 1.56 (1.30, 1.87) <0.0001 4.7 1.52 (1.25, 1.84) <0.0001 4.2 1.09 (0.89, 1.34) 0.3813 0.9 1.03 (0.83, 1.28) 0.7895 0.3 
IL6 1.51 (1.29, 1.78) <0.0001 5.1 1.42 (1.20, 1.68) <0.0001 4.1 1.21 (1.03, 1.43) 0.021 2.3 1.09 (0.92, 1.30) 0.3325 1 
OPN 2 (1.52, 2.63) <0.0001 5 1.81 (1.36, 2.41) <0.0001 4.1 1.5 (1.16, 1.95) 0.0021 3.1 1.36 (1.03, 1.79) 0.0298 2.2 
ADM 2.56 (1.82, 3.59) <0.0001 5.4 2.12 (1.48, 3.05) <0.0001 4.1 1.8 (1.32, 2.45) 0.0002 3.7 1.41 (1.02, 1.96) 0.0389 2.1 
CD40 2.26 (1.68, 3.04) <0.0001 5.4 1.93 (1.41, 2.66) <0.0001 4.1 1.27 (0.94, 1.72) 0.1228 1.5 1.05 (0.76, 1.46) 0.7743 0.3 
MCP3 1.7 (1.35, 2.15) <0.0001 4.5 1.61 (1.27, 2.05) <0.0001 3.9 1.18 (0.89, 1.55) 0.2444 1.2 1.08 (0.81, 1.44) 0.6164 0.5 
TFF3 1.61 (1.32, 1.95) <0.0001 4.8 1.52 (1.23, 1.87) 0.0001 3.9 1.45 (1.15, 1.84) 0.0019 3.1 1.25 (0.96, 1.62) 0.0924 1.7 
FABP4 1.82 (1.51, 2.19) <0.0001 6.2 1.57 (1.25, 1.97) 0.0001 3.9 1.57 (1.29, 1.92) <0.0001 4.5 1.28 (1.01, 1.61) 0.0383 2.1 
OPG_CVD3 2.31 (1.63, 3.27) <0.0001 4.7 2.05 (1.42, 2.95) 0.0001 3.9 1.45 (1.02, 2.06) 0.0385 2.1 1.25 (0.86, 1.82) 0.2381 1.2 
CXCL11 1.34 (1.17, 1.55) <0.0001 4.1 1.33 (1.15, 1.54) 0.0001 3.8 1.11 (0.96, 1.29) 0.1425 1.5 1.13 (0.96, 1.32) 0.1375 1.5 
TNFRSF10A 2.63 (1.88, 3.69) <0.0001 5.6 2.01 (1.40, 2.88) 0.0002 3.8 2.56 (1.74, 3.77) <0.0001 4.8 1.98 (1.31, 3.01) 0.0013 3.2 
TNFR1 2.4 (1.75, 3.28) <0.0001 5.5 1.98 (1.38, 2.84) 0.0002 3.7 1.63 (1.23, 2.16) 0.0007 3.4 1.26 (0.92, 1.73) 0.1488 1.4 
SPON1 2.25 (1.55, 3.26) <0.0001 4.3 2.05 (1.40, 2.98) 0.0002 3.7 1.76 (1.16, 2.67) 0.0083 2.6 1.42 (0.91, 2.21) 0.1225 1.5 
GAL9 2.96 (1.95, 4.49) <0.0001 5.1 2.3 (1.48, 3.58) 0.0002 3.7 3.14 (2.01, 4.91) <0.0001 5 2.59 (1.61, 4.19) <0.0001 3.9 
FGF23 1.7 (1.40, 2.07) <0.0001 5.3 1.48 (1.20, 1.81) 0.0002 3.7 1.84 (1.44, 2.36) <0.0001 4.8 1.69 (1.30, 2.20) <0.0001 3.9 
TNFRSF11A 2.09 (1.61, 2.72) <0.0001 5.6 1.72 (1.28, 2.31) 0.0003 3.6 1.95 (1.47, 2.59) <0.0001 4.6 1.53 (1.12, 2.11) 0.0085 2.6 
IL2RA 1.74 (1.33, 2.28) <0.0001 4.1 1.66 (1.25, 2.22) 0.0005 3.5 1.42 (1.09, 1.84) 0.0092 2.6 1.26 (0.94, 1.67) 0.1163 1.6 
TNFR2 2.11 (1.58, 2.82) <0.0001 5.1 1.75 (1.27, 2.42) 0.0007 3.4 1.55 (1.20, 2.00) 0.0008 3.3 1.29 (0.98, 1.71) 0.0743 1.8 
RETN 1.82 (1.42, 2.33) <0.0001 4.7 1.58 (1.21, 2.06) 0.0008 3.3 1.37 (1.05, 1.77) 0.0182 2.4 1.22 (0.92, 1.62) 0.1584 1.4 
TNFRSF13B 1.74 (1.34, 2.24) <0.0001 4.2 1.58 (1.21, 2.06) 0.0008 3.3 2.61 (1.82, 3.74) <0.0001 5.2 2.33 (1.58, 3.44) <0.0001 4.3 
AGRP 1.82 (1.38, 2.40) <0.0001 4.2 1.64 (1.23, 2.20) 0.0009 3.3 1.9 (1.31, 2.76) 0.0007 3.4 1.62 (1.08, 2.44) 0.0193 2.3 
TNFRSF14 2.09 (1.55, 2.82) <0.0001 4.9 1.76 (1.26, 2.46) 0.0009 3.3 1.52 (1.15, 2.01) 0.0034 2.9 1.26 (0.93, 1.71) 0.1394 1.5 
GAL4 1.89 (1.47, 2.42) <0.0001 5 1.57 (1.19, 2.05) 0.0012 3.2 1.44 (1.10, 1.87) 0.0071 2.7 1.18 (0.89, 1.57) 0.2553 1.1 
RARRES2 3.33 (2.02, 5.51) <0.0001 4.7 2.45 (1.42, 4.23) 0.0014 3.2 2.05 (1.38, 3.05) 0.0004 3.5 1.67 (1.09, 2.56) 0.0183 2.4 
ACE2 1.6 (1.27, 2.02) <0.0001 4 1.48 (1.16, 1.89) 0.0014 3.2 1.52 (1.17, 1.98) 0.0016 3.2 1.4 (1.06, 1.84) 0.0173 2.4 
PLGF 2.17 (1.54, 3.06) <0.0001 4.4 1.86 (1.27, 2.72) 0.0014 3.2 1.95 (1.38, 2.75) 0.0002 3.8 1.61 (1.11, 2.34) 0.0131 2.5 
PGLYRP1 1.68 (1.31, 2.15) <0.0001 4.1 1.53 (1.17, 1.98) 0.0016 3.2 1.36 (1.06, 1.74) 0.0151 2.4 1.2 (0.92, 1.56) 0.1893 1.3 
TGFALPHA 1.9 (1.40, 2.59) <0.0001 4.1 1.66 (1.21, 2.28) 0.0016 3.2 1.38 (1.07, 1.78) 0.0122 2.5 1.23 (0.94, 1.61) 0.1345 1.5 
MMP12 1.64 (1.32, 2.03) <0.0001 4.6 1.42 (1.13, 1.79) 0.0023 3 1.54 (1.23, 1.92) 0.0002 3.8 1.33 (1.04, 1.70) 0.0236 2.3 
TIMP4 1.72 (1.32, 2.23) <0.0001 4 1.54 (1.17, 2.04) 0.0024 3 1.2 (0.93, 1.53) 0.1568 1.4 1.08 (0.83, 1.41) 0.5465 0.6 
SLAMF7 1.55 (1.26, 1.91) <0.0001 4.1 1.41 (1.13, 1.76) 0.0024 3 2.16 (1.52, 3.06) <0.0001 4.3 2 (1.38, 2.91) 0.0003 3.7 
TNFRSF9 1.54 (1.25, 1.90) <0.0001 4 1.41 (1.13, 1.76) 0.0025 3 1.33 (1.03, 1.72) 0.0318 2.1 1.15 (0.86, 1.53) 0.3411 1 
IL1RA 1.54 (1.27, 1.86) <0.0001 4.4 1.37 (1.11, 1.69) 0.003 3 1.25 (1.07, 1.46) 0.0048 2.8 1.17 (0.99, 1.39) 0.059 1.9 
CCL16 1.47 (1.21, 1.79) <0.0001 3.9 1.37 (1.11, 1.68) 0.003 3 1.72 (1.34, 2.22) <0.0001 4.2 1.55 (1.18, 2.02) 0.0015 3.2 
CD4 2.06 (1.49, 2.85) <0.0001 4.3 1.67 (1.18, 2.35) 0.0035 2.9 2.17 (1.49, 3.16) <0.0001 4 1.86 (1.25, 2.77) 0.0021 3.1 
LTBR 1.93 (1.40, 2.68) <0.0001 4 1.7 (1.18, 2.45) 0.004 2.9 1.42 (1.06, 1.90) 0.0203 2.3 1.22 (0.88, 1.68) 0.2287 1.2 
IL15RA 2.12 (1.47, 3.05) <0.0001 4 1.74 (1.18, 2.56) 0.0053 2.8 1.75 (1.07, 2.85) 0.0258 2.2 1.46 (0.86, 2.49) 0.1579 1.4 
KIM1 1.41 (1.19, 1.68) <0.0001 4 1.29 (1.07, 1.55) 0.0065 2.7 1.51 (1.23, 1.84) <0.0001 4 1.31 (1.05, 1.62) 0.0159 2.4 
PLC 2.26 (1.59, 3.21) <0.0001 4.5 1.77 (1.17, 2.68) 0.0071 2.7 1.76 (1.24, 2.49) 0.0015 3.2 1.43 (0.97, 2.11) 0.0686 1.8 
CEACAM8 1.51 (1.22, 1.86) 0.0001 3.8 1.47 (1.18, 1.83) 0.0006 3.4 1.49 (1.19, 1.86) 0.0005 3.5 1.36 (1.08, 1.73) 0.0098 2.6 
ICAM2 1.91 (1.37, 2.66) 0.0001 3.8 1.73 (1.22, 2.44) 0.0019 3.1 1.16 (0.86, 1.57) 0.3262 1 1.06 (0.77, 1.45) 0.7229 0.4 
EPHB4 1.96 (1.40, 2.76) 0.0001 3.9 1.62 (1.11, 2.37) 0.0121 2.5 1.38 (1.00, 1.91) 0.0499 2 1.19 (0.84, 1.69) 0.3334 1 
HSP27 2.13 (1.42, 3.22) 0.0003 3.6 2.03 (1.32, 3.14) 0.0013 3.2 1.32 (1.02, 1.71) 0.0357 2.1 1.27 (0.97, 1.68) 0.0826 1.7 
LAPTGFBETA1 1.68 (1.27, 2.22) 0.0003 3.6 1.58 (1.18, 2.12) 0.0021 3.1 1.15 (0.88, 1.49) 0.3102 1 1.11 (0.84, 1.47) 0.4747 0.7 
PAR1 1.86 (1.33, 2.60) 0.0003 3.6 1.64 (1.16, 2.31) 0.0048 2.8 1.74 (1.24, 2.45) 0.0014 3.2 1.53 (1.07, 2.19) 0.0186 2.4 
TWEAK 0.51 (0.36, 0.73) 0.0003 3.6 0.58 (0.39, 0.85) 0.0052 2.8 0.53 (0.39, 0.71) <0.0001 4.1 0.58 (0.42, 0.80) 0.0008 3.4 
CXCL16 1.95 (1.36, 2.79) 0.0003 3.6 1.66 (1.13, 2.46) 0.0101 2.6 1.29 (0.93, 1.81) 0.1317 1.5 1.12 (0.78, 1.60) 0.5478 0.6 
JAMA 1.43 (1.18, 1.73) 0.0003 3.6 1.29 (1.06, 1.58) 0.0122 2.5 1.11 (0.94, 1.32) 0.2257 1.2 1.07 (0.90, 1.28) 0.4462 0.8 
IL18BP 1.71 (1.28, 2.29) 0.0003 3.6 1.5 (1.09, 2.07) 0.013 2.5 1.39 (1.06, 1.83) 0.0192 2.3 1.18 (0.87, 1.59) 0.2842 1.1 
CCL15 1.51 (1.21, 1.88) 0.0003 3.6 1.29 (1.00, 1.65) 0.0463 2 1.39 (1.08, 1.79) 0.0117 2.5 1.18 (0.89, 1.57) 0.238 1.2 
CHI3L1 1.33 (1.14, 1.56) 0.0004 3.5 1.25 (1.06, 1.47) 0.0086 2.6 1.2 (1.01, 1.42) 0.0352 2.1 1.08 (0.90, 1.29) 0.4317 0.8 
CSF1 2.27 (1.43, 3.61) 0.0005 3.5 1.91 (1.18, 3.09) 0.0088 2.6 1.37 (0.78, 2.42) 0.2774 1.1 1.05 (0.57, 1.93) 0.8707 0.2 
PDL1 1.64 (1.24, 2.16) 0.0005 3.5 1.47 (1.09, 1.98) 0.0107 2.6 1.3 (0.93, 1.81) 0.1215 1.5 0.96 (0.67, 1.39) 0.8473 0.2 
PDL2 1.96 (1.34, 2.87) 0.0005 3.5 1.68 (1.13, 2.50) 0.011 2.5 1.77 (1.18, 2.65) 0.006 2.7 1.62 (1.05, 2.50) 0.0287 2.2 
FAS 1.78 (1.29, 2.46) 0.0005 3.5 1.49 (1.06, 2.09) 0.0223 2.3 1.52 (1.10, 2.11) 0.012 2.5 1.29 (0.90, 1.84) 0.1601 1.4 
GRN 2.09 (1.38, 3.16) 0.0005 3.5 1.66 (1.07, 2.57) 0.0239 2.3 1.41 (0.96, 2.08) 0.0811 1.7 1.16 (0.76, 1.75) 0.4918 0.7 
SLAMF1 1.44 (1.17, 1.76) 0.0005 3.5 1.27 (1.02, 1.58) 0.0293 2.2 1.62 (1.23, 2.13) 0.0005 3.5 1.42 (1.06, 1.89) 0.0175 2.4 
CTSZ 1.74 (1.27, 2.39) 0.0005 3.5 1.44 (1.03, 2.02) 0.0321 2.1 1.32 (0.97, 1.78) 0.0748 1.8 1.09 (0.79, 1.52) 0.5884 0.5 
IGFBP7 1.66 (1.24, 2.23) 0.0006 3.4 1.42 (1.04, 1.94) 0.0259 2.2 1.6 (1.21, 2.11) 0.001 3.3 1.42 (1.05, 1.91) 0.021 2.3 
IL16 1.54 (1.20, 1.97) 0.0007 3.4 1.38 (1.06, 1.79) 0.016 2.4 1.46 (1.15, 1.86) 0.0019 3.1 1.34 (1.04, 1.72) 0.0232 2.3 
CCL25 1.51 (1.18, 1.94) 0.0009 3.3 1.35 (1.04, 1.75) 0.0234 2.3 0.96 (0.72, 1.29) 0.8091 0.2 0.85 (0.62, 1.17) 0.3243 1 
IL12B 1.4 (1.14, 1.72) 0.0011 3.3 1.3 (1.05, 1.62) 0.0173 2.4 1.25 (1.00, 1.56) 0.0476 2 1.12 (0.88, 1.43) 0.3453 0.9 
PON3 0.71 (0.58, 0.87) 0.0011 3.3 0.83 (0.66, 1.04) 0.0977 1.7 0.64 (0.51, 0.80) <0.0001 3.9 0.72 (0.56, 0.91) 0.0064 2.7 
IGFBP1 1.26 (1.09, 1.45) 0.0013 3.2 1.41 (1.19, 1.66) <0.0001 4.1 1.08 (0.92, 1.26) 0.3564 0.9 1.14 (0.95, 1.37) 0.153 1.4 
CCL23 1.6 (1.20, 2.14) 0.0014 3.2 1.74 (1.28, 2.37) 0.0005 3.5 1.08 (0.79, 1.47) 0.6256 0.5 0.98 (0.70, 1.37) 0.9144 0.1 
DECR1 1.19 (1.07, 1.33) 0.0014 3.2 1.17 (1.04, 1.31) 0.0085 2.6 1.03 (0.93, 1.15) 0.5695 0.6 1.02 (0.91, 1.15) 0.7041 0.4 
SPON2 2.86 (1.50, 5.48) 0.0015 3.2 2.66 (1.36, 5.21) 0.0044 2.8 2.4 (1.36, 4.25) 0.0026 3 2.1 (1.16, 3.79) 0.0137 2.5 
TM 1.9 (1.27, 2.82) 0.0016 3.2 1.63 (1.07, 2.48) 0.0233 2.3 1.5 (1.03, 2.19) 0.0354 2.1 1.24 (0.85, 1.82) 0.2637 1.1 
REN 1.31 (1.11, 1.55) 0.0018 3.1 1.18 (0.98, 1.41) 0.0772 1.8 1.54 (1.29, 1.85) <0.0001 4.7 1.38 (1.13, 1.68) 0.0014 3.2 
MMP3 1.4 (1.13, 1.74) 0.0021 3.1 1.37 (1.09, 1.73) 0.0062 2.7 1.17 (0.94, 1.45) 0.1521 1.4 1.05 (0.83, 1.33) 0.673 0.4 
CASP8 1.26 (1.09, 1.47) 0.0021 3.1 1.22 (1.04, 1.43) 0.0126 2.5 1.19 (1.03, 1.37) 0.0148 2.4 1.18 (1.02, 1.37) 0.0286 2.2 
TLT2 1.49 (1.16, 1.93) 0.0021 3.1 1.39 (1.06, 1.82) 0.0169 2.4 1.06 (0.80, 1.40) 0.6846 0.4 0.98 (0.73, 1.32) 0.9002 0.1 
MMP2 1.64 (1.19, 2.24) 0.0023 3 1.55 (1.11, 2.16) 0.0096 2.6 1.38 (1.01, 1.88) 0.0452 2 1.38 (0.99, 1.91) 0.0553 1.9 
IL10RB 1.77 (1.22, 2.56) 0.0024 3 1.56 (1.06, 2.30) 0.0247 2.2 1.27 (0.83, 1.92) 0.2708 1.1 0.92 (0.58, 1.46) 0.7309 0.3 
GAL3 1.52 (1.16, 2.00) 0.0025 3 1.44 (1.08, 1.92) 0.012 2.5 1.17 (0.89, 1.54) 0.2714 1.1 1.02 (0.76, 1.37) 0.887 0.1 
CD163 1.46 (1.14, 1.87) 0.0025 3 1.35 (1.05, 1.75) 0.0198 2.3 1.07 (0.84, 1.35) 0.581 0.6 0.99 (0.77, 1.27) 0.9236 0.1 
VSIG2 1.43 (1.14, 1.81) 0.0025 3 1.24 (0.96, 1.59) 0.0967 1.7 1.76 (1.33, 2.32) <0.0001 4 1.46 (1.06, 2.01) 0.02 2.3 
TR 1.37 (1.12, 1.69) 0.0028 3 1.29 (1.04, 1.61) 0.0202 2.3 1.24 (0.99, 1.55) 0.0663 1.8 1.12 (0.88, 1.43) 0.3645 0.9 
CCL20 1.21 (1.07, 1.38) 0.003 3 1.17 (1.02, 1.33) 0.0223 2.3 1.06 (0.94, 1.21) 0.3405 1 1.03 (0.90, 1.18) 0.6877 0.4 
NEMO 1.19 (1.06, 1.34) 0.0032 2.9 1.16 (1.02, 1.31) 0.0224 2.3 1.07 (0.93, 1.23) 0.3387 1 1.04 (0.90, 1.21) 0.5799 0.6 
IL4RA* 1.52 (1.15, 2.02) 0.0033 2.9 1.42 (1.06, 1.90) 0.0171 2.4 1.62 (1.18, 2.22) 0.0029 3 1.45 (1.03, 2.03) 0.0309 2.2 
MERTK 1.66 (1.18, 2.33) 0.0038 2.9 1.6 (1.12, 2.28) 0.0101 2.6 1.38 (0.96, 1.99) 0.0863 1.7 1.29 (0.87, 1.91) 0.2016 1.3 
IL17C 1.41 (1.12, 1.77) 0.0038 2.9 1.29 (1.01, 1.65) 0.0398 2.1 1.07 (0.80, 1.44) 0.6416 0.5 1.02 (0.75, 1.39) 0.8845 0.1 
CXCL10 1.28 (1.08, 1.52) 0.0042 2.9 1.26 (1.05, 1.51) 0.0116 2.5 1.05 (0.88, 1.25) 0.5963 0.5 1.08 (0.89, 1.29) 0.437 0.8 
ENRAGE 1.26 (1.08, 1.47) 0.0042 2.9 1.23 (1.04, 1.46) 0.0137 2.5 1.54 (1.25, 1.90) <0.0001 4 1.44 (1.15, 1.81) 0.0016 3.2 
BETANGF 1.66 (1.16, 2.36) 0.005 2.8 1.38 (0.95, 2.00) 0.0917 1.7 1.15 (0.77, 1.72) 0.4889 0.7 1.06 (0.70, 1.62) 0.7691 0.3 
LOX1 1.39 (1.10, 1.76) 0.0054 2.8 1.36 (1.07, 1.74) 0.0129 2.5 1.49 (1.19, 1.86) 0.0005 3.5 1.46 (1.15, 1.86) 0.0018 3.1 
MMP10 1.34 (1.09, 1.66) 0.0055 2.8 1.25 (1.00, 1.55) 0.0463 2 0.88 (0.68, 1.14) 0.3391 1 0.76 (0.57, 1.00) 0.0518 1.9 
PECAM1 1.51 (1.13, 2.01) 0.0058 2.8 1.41 (1.04, 1.91) 0.0267 2.2 1.05 (0.81, 1.35) 0.7106 0.4 1.06 (0.81, 1.38) 0.6884 0.4 
IL10 1.35 (1.09, 1.67) 0.0062 2.7 1.31 (1.05, 1.63) 0.0161 2.4 1.03 (0.84, 1.27) 0.7601 0.3 0.96 (0.78, 1.20) 0.742 0.3 
LIFR 1.68 (1.16, 2.45) 0.0067 2.7 1.44 (0.97, 2.14) 0.0679 1.8 1.15 (0.75, 1.76) 0.5178 0.6 0.94 (0.60, 1.49) 0.7975 0.3 
HOSCAR 2.11 (1.23, 3.64) 0.0069 2.7 1.93 (1.09, 3.39) 0.023 2.3 1.93 (1.12, 3.32) 0.0175 2.4 1.68 (0.95, 2.97) 0.0764 1.8 
IGFBP2 1.35 (1.08, 1.68) 0.0072 2.7 1.55 (1.21, 1.99) 0.0005 3.5 1.25 (0.99, 1.58) 0.0628 1.9 1.35 (1.03, 1.77) 0.0298 2.2 
CDCP1 1.34 (1.08, 1.66) 0.0074 2.7 1.26 (1.01, 1.59) 0.0431 2 0.98 (0.76, 1.26) 0.8736 0.2 0.85 (0.65, 1.11) 0.2395 1.2 
MCP2 1.36 (1.09, 1.70) 0.0075 2.7 1.35 (1.07, 1.71) 0.0127 2.5 1.13 (0.91, 1.41) 0.2737 1.1 1.11 (0.88, 1.41) 0.3724 0.9 
CX3CL1 1.48 (1.11, 1.97) 0.0075 2.7 1.3 (0.96, 1.77) 0.0926 1.7 1.18 (0.87, 1.60) 0.2787 1.1 1.01 (0.72, 1.41) 0.9603 0 
PRTN3 1.35 (1.08, 1.68) 0.0081 2.6 1.3 (1.04, 1.64) 0.0238 2.3 1.26 (0.99, 1.59) 0.0557 1.9 1.18 (0.92, 1.51) 0.1911 1.3 
AXIN1 1.16 (1.04, 1.29) 0.0085 2.6 1.13 (1.01, 1.26) 0.0403 2.1 0.96 (0.84, 1.10) 0.5615 0.6 0.94 (0.81, 1.09) 0.4114 0.8 
MPO 1.43 (1.09, 1.86) 0.009 2.6 1.36 (1.03, 1.79) 0.0323 2.1 1.17 (0.90, 1.51) 0.2337 1.2 1.09 (0.83, 1.43) 0.524 0.6 
GT 1.27 (1.06, 1.53) 0.0101 2.6 1.19 (0.97, 1.44) 0.088 1.7 1.3 (1.02, 1.67) 0.037 2.1 1.26 (0.96, 1.65) 0.092 1.7 
SORT1 1.93 (1.17, 3.18) 0.0103 2.6 1.99 (1.17, 3.38) 0.0107 2.6 1.68 (1.08, 2.62) 0.0218 2.3 1.8 (1.12, 2.89) 0.0149 2.4 
ST1A1 1.16 (1.04, 1.31) 0.0103 2.6 1.13 (1.00, 1.27) 0.0593 1.9 1.02 (0.91, 1.15) 0.7111 0.4 1.01 (0.89, 1.15) 0.8863 0.1 
CCL11 1.45 (1.09, 1.93) 0.0104 2.6 1.41 (1.05, 1.91) 0.0242 2.3 1.46 (1.06, 1.99) 0.019 2.3 1.36 (0.97, 1.91) 0.0734 1.8 
CST5 1.35 (1.07, 1.70) 0.0113 2.5 1.19 (0.92, 1.54) 0.1858 1.3 1.01 (0.76, 1.35) 0.9334 0.1 0.85 (0.62, 1.18) 0.3325 1 
SELP 1.33 (1.07, 1.67) 0.0121 2.5 1.26 (1.00, 1.60) 0.0529 1.9 1.12 (0.91, 1.37) 0.3031 1 1.11 (0.89, 1.39) 0.3584 0.9 
BP1_4E 1.17 (1.04, 1.33) 0.0121 2.5 1.14 (1.00, 1.30) 0.0541 1.9 1.17 (1.02, 1.34) 0.0254 2.2 1.12 (0.97, 1.29) 0.135 1.5 
SIRT2 1.13 (1.03, 1.24) 0.0131 2.5 1.11 (1.00, 1.22) 0.049 2 1.05 (0.94, 1.17) 0.3818 0.9 1.03 (0.92, 1.15) 0.6376 0.5 
ST2 1.37 (1.07, 1.75) 0.0131 2.5 1.25 (0.97, 1.62) 0.0861 1.7 1.42 (1.09, 1.83) 0.0083 2.6 1.33 (1.01, 1.76) 0.0395 2.1 
CASP3 1.15 (1.03, 1.28) 0.0133 2.5 1.12 (1.00, 1.26) 0.0486 2 1.04 (0.93, 1.17) 0.4996 0.7 1.02 (0.90, 1.16) 0.7465 0.3 
PRSS8 1.62 (1.11, 2.38) 0.0133 2.5 1.39 (0.93, 2.07) 0.1063 1.6 1.3 (1.04, 1.63) 0.0193 2.3 1.21 (0.96, 1.53) 0.1148 1.6 
VWF 1.18 (1.04, 1.35) 0.0135 2.5 1.15 (1.00, 1.32) 0.0539 1.9 1.18 (1.03, 1.36) 0.0153 2.4 1.17 (1.01, 1.35) 0.0347 2.1 
FGF21 1.15 (1.03, 1.28) 0.0139 2.5 1.08 (0.96, 1.21) 0.2096 1.3 1.15 (1.03, 1.30) 0.0161 2.4 1.07 (0.95, 1.22) 0.272 1.1 
TGM2 1.26 (1.05, 1.51) 0.0144 2.4 1.22 (1.01, 1.48) 0.0383 2.1 1.43 (1.18, 1.73) 0.0003 3.6 1.55 (1.25, 1.91) <0.0001 4 
IL1RT1 1.58 (1.09, 2.28) 0.0145 2.4 1.39 (0.94, 2.06) 0.0991 1.6 1.18 (0.86, 1.62) 0.3017 1 1.07 (0.76, 1.49) 0.704 0.4 
CD244 1.48 (1.08, 2.04) 0.0154 2.4 1.36 (0.97, 1.90) 0.0737 1.8 0.79 (0.55, 1.12) 0.1841 1.3 0.7 (0.48, 1.02) 0.0603 1.9 
MCP1_CVD3 1.27 (1.05, 1.55) 0.0162 2.4 1.23 (1.02, 1.49) 0.0308 2.2 1.14 (0.91, 1.43) 0.265 1.1 1.09 (0.86, 1.38) 0.4702 0.7 
CD93 1.6 (1.09, 2.35) 0.0163 2.4 1.38 (0.91, 2.09) 0.1272 1.5 1.62 (1.12, 2.35) 0.0107 2.6 1.44 (0.96, 2.15) 0.0793 1.8 
PCSK9 1.43 (1.07, 1.93) 0.0171 2.4 1.32 (0.97, 1.79) 0.0791 1.8 1 (0.74, 1.36) 0.982 0 0.91 (0.66, 1.25) 0.5486 0.6 
PI3 1.27 (1.04, 1.54) 0.0174 2.4 1.08 (0.87, 1.35) 0.4985 0.7 1.21 (1.01, 1.45) 0.0384 2.1 1.09 (0.90, 1.32) 0.3972 0.8 
IL6RA 1.5 (1.07, 2.10) 0.0192 2.3 1.58 (1.10, 2.25) 0.0126 2.5 1.21 (0.89, 1.63) 0.228 1.2 1.17 (0.85, 1.61) 0.3472 0.9 
VEGFD 1.52 (1.07, 2.17) 0.0205 2.3 1.75 (1.19, 2.58) 0.0045 2.8 1.81 (1.29, 2.54) 0.0007 3.4 1.98 (1.36, 2.89) 0.0004 3.6 
TNFSF14 1.28 (1.04, 1.57) 0.0212 2.3 1.22 (0.98, 1.52) 0.0795 1.8 1.14 (0.94, 1.38) 0.1775 1.3 1.17 (0.96, 1.44) 0.1236 1.5 
ITGB1BP2 1.11 (1.02, 1.21) 0.0213 2.3 1.09 (0.99, 1.19) 0.0842 1.7 1.03 (0.93, 1.14) 0.5949 0.5 1.01 (0.90, 1.12) 0.9105 0.1 
FABP2 1.27 (1.03, 1.56) 0.0223 2.3 1.2 (0.97, 1.50) 0.0998 1.6 1.32 (1.06, 1.63) 0.0119 2.5 1.19 (0.95, 1.49) 0.1356 1.5 
BLMH 1.44 (1.05, 1.96) 0.0224 2.3 1.5 (1.08, 2.09) 0.0154 2.4 0.79 (0.58, 1.07) 0.1287 1.5 0.83 (0.60, 1.15) 0.2558 1.1 
SRC 1.19 (1.02, 1.38) 0.0231 2.3 1.15 (0.99, 1.35) 0.0733 1.8 1.07 (0.92, 1.26) 0.3867 0.9 1.03 (0.87, 1.21) 0.7691 0.3 
IL8 1.2 (1.03, 1.40) 0.0232 2.3 1.18 (1.00, 1.39) 0.0508 2 1.13 (0.94, 1.36) 0.2025 1.3 1.1 (0.90, 1.33) 0.3563 0.9 
SELE 1.37 (1.04, 1.79) 0.0239 2.3 1.13 (0.85, 1.51) 0.409 0.8 1.31 (0.99, 1.75) 0.0624 1.9 1.18 (0.87, 1.60) 0.2917 1.1 
LEP 1.17 (1.02, 1.35) 0.0246 2.2 1.01 (0.84, 1.21) 0.9082 0.1 1.22 (1.04, 1.43) 0.0148 2.4 1.03 (0.83, 1.28) 0.7984 0.3 
PSPD 1.22 (1.02, 1.46) 0.0262 2.2 1.27 (1.05, 1.54) 0.0122 2.5 1.29 (1.03, 1.61) 0.0236 2.3 1.32 (1.05, 1.67) 0.0194 2.3 
IL18R1 1.42 (1.04, 1.94) 0.0266 2.2 1.2 (0.86, 1.66) 0.2856 1.1 1.2 (0.84, 1.72) 0.3199 1 0.96 (0.65, 1.41) 0.8428 0.2 
SOD2 2.01 (1.08, 3.73) 0.0274 2.2 2.3 (1.20, 4.42) 0.0122 2.5 1.46 (0.87, 2.45) 0.1539 1.4 1.53 (0.88, 2.66) 0.1353 1.5 
NT3 1.37 (1.04, 1.82) 0.0274 2.2 1.29 (0.96, 1.74) 0.0929 1.7 0.95 (0.74, 1.23) 0.7178 0.4 1 (0.76, 1.30) 0.986 0 
BMP6 1.23 (1.02, 1.47) 0.0278 2.2 1.17 (0.97, 1.42) 0.1076 1.6 1.09 (0.91, 1.31) 0.3624 0.9 1.08 (0.88, 1.31) 0.4708 0.7 
APN 1.53 (1.05, 2.23) 0.0279 2.2 1.37 (0.92, 2.04) 0.1161 1.6 0.96 (0.68, 1.34) 0.7958 0.3 0.92 (0.64, 1.32) 0.6636 0.4 
STK4 1.13 (1.01, 1.26) 0.0285 2.2 1.1 (0.98, 1.24) 0.0908 1.7 1.06 (0.94, 1.20) 0.3107 1 1.04 (0.92, 1.18) 0.5008 0.7 
AMBP 1.98 (1.07, 3.64) 0.0285 2.2 1.63 (0.85, 3.12) 0.1424 1.5 2.48 (1.35, 4.55) 0.0034 2.9 1.86 (0.97, 3.53) 0.06 1.9 
IL27 1.46 (1.04, 2.05) 0.0303 2.2 1.57 (1.10, 2.26) 0.014 2.5 1.83 (1.22, 2.74) 0.0036 2.9 1.77 (1.15, 2.72) 0.0095 2.6 
CTSL1 1.49 (1.04, 2.13) 0.0314 2.2 1.51 (1.03, 2.20) 0.0331 2.1 1.31 (0.95, 1.79) 0.0972 1.7 1.26 (0.90, 1.76) 0.1822 1.3 
TNFSF13B 1.45 (1.03, 2.05) 0.0322 2.1 1.35 (0.94, 1.94) 0.1018 1.6 1.04 (0.76, 1.42) 0.819 0.2 1.04 (0.75, 1.44) 0.8279 0.2 
MMP1 1.13 (1.01, 1.28) 0.0346 2.1 1.1 (0.97, 1.24) 0.1339 1.5 1.1 (0.96, 1.25) 0.158 1.4 1.06 (0.92, 1.22) 0.398 0.8 
SHPS1 1.38 (1.02, 1.86) 0.0347 2.1 1.14 (0.83, 1.58) 0.4173 0.8 1.19 (0.91, 1.54) 0.1971 1.3 1.07 (0.81, 1.42) 0.6111 0.5 
MMP7 1.18 (1.01, 1.39) 0.0352 2.1 1.12 (0.95, 1.32) 0.1941 1.3 1.1 (0.96, 1.25) 0.1669 1.4 1.1 (0.96, 1.26) 0.1809 1.3 
IL18 1.21 (1.01, 1.45) 0.0366 2.1 1.16 (0.97, 1.41) 0.1113 1.6 1.27 (1.07, 1.51) 0.0074 2.7 1.24 (1.03, 1.49) 0.0239 2.3 
STAMPB 1.14 (1.01, 1.29) 0.0367 2.1 1.11 (0.97, 1.26) 0.1225 1.5 1.03 (0.89, 1.20) 0.6566 0.4 1 (0.86, 1.18) 0.9529 0.1 
TF 1.44 (1.02, 2.03) 0.0385 2.1 1.24 (0.86, 1.78) 0.2487 1.2 1.55 (1.05, 2.31) 0.0285 2.2 1.35 (0.89, 2.05) 0.159 1.4 
ITGB2 1.38 (1.02, 1.87) 0.0387 2.1 1.31 (0.95, 1.81) 0.0988 1.7 1.02 (0.79, 1.31) 0.8783 0.2 1.01 (0.77, 1.33) 0.9216 0.1 
OSM 1.19 (1.01, 1.41) 0.0395 2.1 1.18 (0.99, 1.41) 0.0644 1.8 1.19 (1.01, 1.40) 0.0334 2.1 1.14 (0.96, 1.36) 0.1331 1.5 
XCL1 1.26 (1.01, 1.57) 0.0403 2.1 1.18 (0.94, 1.49) 0.1584 1.4 1.33 (1.04, 1.70) 0.0235 2.3 1.26 (0.97, 1.64) 0.0808 1.7 
CCL19 1.16 (1.01, 1.34) 0.0403 2.1 1.08 (0.93, 1.26) 0.3193 1 1.23 (1.04, 1.47) 0.0164 2.4 1.21 (1.01, 1.45) 0.0414 2 
DKK1 1.27 (1.01, 1.61) 0.0443 2 1.27 (0.99, 1.63) 0.0579 1.9 1.19 (0.97, 1.46) 0.0952 1.7 1.21 (0.97, 1.51) 0.091 1.7 
ALCAM 1.42 (1.00, 2.02) 0.0486 2 1.33 (0.92, 1.92) 0.126 1.5 1.1 (0.79, 1.52) 0.5788 0.6 1.03 (0.73, 1.46) 0.8773 0.2 
PTX3 1.25 (0.99, 1.58) 0.0597 1.9 1.24 (0.97, 1.59) 0.0816 1.7 1.31 (0.97, 1.78) 0.0778 1.8 1.43 (1.03, 1.97) 0.0302 2.2 
IL17D 1.38 (0.99, 1.94) 0.06 1.9 1.37 (0.96, 1.95) 0.0816 1.7 1.22 (0.79, 1.89) 0.3631 0.9 1.28 (0.80, 2.03) 0.3057 1 
HGDNF 1.3 (0.98, 1.72) 0.0687 1.8 1.05 (0.78, 1.43) 0.7318 0.3 1.17 (0.80, 1.72) 0.4178 0.8 1.02 (0.68, 1.54) 0.9082 0.1 
CXCL6 1.17 (0.99, 1.38) 0.069 1.8 1.18 (0.99, 1.40) 0.0677 1.8 0.99 (0.84, 1.18) 0.9326 0.1 1.01 (0.84, 1.21) 0.9013 0.1 
FGF19 1.15 (0.99, 1.35) 0.0722 1.8 1.14 (0.97, 1.35) 0.1164 1.6 0.93 (0.78, 1.10) 0.387 0.9 0.89 (0.74, 1.08) 0.2396 1.2 
IL17A 1.25 (0.98, 1.61) 0.0779 1.8 1.18 (0.91, 1.53) 0.2225 1.2 0.93 (0.67, 1.30) 0.6714 0.4 0.94 (0.67, 1.33) 0.7287 0.3 
IGGFCRECEPTORIIB 1.23 (0.98, 1.54) 0.0784 1.8 1.25 (0.98, 1.58) 0.0672 1.8 1.18 (0.86, 1.60) 0.3064 1 1.13 (0.81, 1.57) 0.466 0.7 
PARP1 1.13 (0.99, 1.29) 0.0805 1.7 1.1 (0.95, 1.27) 0.2035 1.3 1.16 (1.00, 1.36) 0.0535 1.9 1.19 (1.00, 1.40) 0.0435 2 
IDUA 1.26 (0.97, 1.64) 0.0834 1.7 1.25 (0.95, 1.64) 0.1091 1.6 1.03 (0.82, 1.30) 0.7905 0.3 0.94 (0.74, 1.21) 0.6409 0.5 
PDGFSUBUNITB 1.12 (0.98, 1.27) 0.0855 1.7 1.13 (0.99, 1.29) 0.0757 1.8 1.09 (0.94, 1.27) 0.2374 1.2 1.09 (0.93, 1.28) 0.2947 1 
CD40L 1.1 (0.99, 1.23) 0.0899 1.7 1.09 (0.97, 1.23) 0.1281 1.5 1.07 (0.96, 1.20) 0.2244 1.2 1.09 (0.97, 1.23) 0.1406 1.5 
TNFRSF10C 1.26 (0.96, 1.64) 0.0925 1.7 1.09 (0.83, 1.45) 0.5284 0.6 1.22 (0.94, 1.59) 0.1351 1.5 1.12 (0.85, 1.48) 0.4103 0.8 
CTSD 1.28 (0.96, 1.70) 0.0931 1.7 1.06 (0.78, 1.43) 0.7145 0.4 1.06 (0.81, 1.38) 0.6892 0.4 0.93 (0.70, 1.24) 0.6154 0.5 
NOTCH3 1.3 (0.96, 1.75) 0.0936 1.7 1.17 (0.85, 1.61) 0.3379 1 1.1 (0.82, 1.49) 0.5157 0.7 1.1 (0.80, 1.51) 0.5684 0.6 
MB 1.21 (0.97, 1.50) 0.0947 1.7 1.02 (0.80, 1.30) 0.894 0.1 0.98 (0.78, 1.22) 0.8252 0.2 0.85 (0.66, 1.09) 0.1947 1.3 
CD5 1.25 (0.96, 1.63) 0.0956 1.7 1.11 (0.84, 1.48) 0.4591 0.7 1.28 (0.91, 1.79) 0.1504 1.4 1.08 (0.75, 1.55) 0.6754 0.4 
TPA 1.21 (0.97, 1.50) 0.0975 1.7 1.11 (0.88, 1.41) 0.3743 0.9 0.99 (0.82, 1.20) 0.9333 0.1 0.96 (0.78, 1.17) 0.6772 0.4 
PAPPA 1.22 (0.96, 1.55) 0.0995 1.6 1.28 (1.00, 1.65) 0.0535 1.9 1.15 (0.88, 1.50) 0.2964 1 1.32 (0.99, 1.75) 0.0579 1.9 
COL1A1 1.29 (0.95, 1.75) 0.0996 1.6 1.11 (0.81, 1.54) 0.5109 0.7 1.16 (0.84, 1.61) 0.3769 0.9 1.1 (0.78, 1.56) 0.5765 0.6 
IL7 1.17 (0.97, 1.41) 0.1021 1.6 1.19 (0.98, 1.45) 0.086 1.7 0.96 (0.78, 1.17) 0.6572 0.4 0.96 (0.78, 1.19) 0.7271 0.3 
CCL4 1.16 (0.96, 1.40) 0.1143 1.6 1.14 (0.94, 1.39) 0.1714 1.4 0.98 (0.81, 1.19) 0.8406 0.2 0.96 (0.78, 1.18) 0.7178 0.4 
SCF 0.73 (0.50, 1.08) 0.115 1.6 0.73 (0.48, 1.09) 0.1228 1.5 1.3 (0.93, 1.82) 0.1216 1.5 1.25 (0.88, 1.77) 0.2118 1.2 
CA5A 1.13 (0.97, 1.31) 0.1184 1.6 0.99 (0.84, 1.16) 0.8755 0.2 1.08 (0.90, 1.31) 0.4065 0.8 0.95 (0.77, 1.16) 0.6048 0.5 
PRELP 1.58 (0.89, 2.82) 0.1185 1.6 1.36 (0.74, 2.49) 0.321 1 3.17 (1.55, 6.49) 0.0016 3.2 2.79 (1.31, 5.94) 0.008 2.7 
FS 1.29 (0.93, 1.78) 0.1237 1.5 1.24 (0.88, 1.73) 0.2173 1.2 1.4 (1.02, 1.92) 0.039 2.1 1.37 (0.98, 1.91) 0.0637 1.9 
CCL17 1.11 (0.97, 1.28) 0.1284 1.5 1.12 (0.97, 1.29) 0.1299 1.5 1.2 (1.04, 1.38) 0.0144 2.4 1.22 (1.04, 1.42) 0.0131 2.5 
HBEGF 1.27 (0.92, 1.74) 0.1412 1.5 1.25 (0.90, 1.75) 0.1831 1.3 1.29 (0.99, 1.67) 0.0569 1.9 1.34 (1.01, 1.77) 0.04 2.1 
ADA 1.21 (0.93, 1.57) 0.1589 1.4 1.11 (0.85, 1.46) 0.4453 0.8 0.84 (0.62, 1.13) 0.2553 1.1 0.83 (0.61, 1.14) 0.256 1.1 
MMP9 1.12 (0.96, 1.30) 0.1601 1.4 1.11 (0.95, 1.31) 0.1942 1.3 1.21 (1.04, 1.41) 0.0135 2.5 1.18 (1.00, 1.39) 0.048 2 
PAI 1.12 (0.96, 1.31) 0.1612 1.4 1.07 (0.91, 1.27) 0.4117 0.8 1.02 (0.87, 1.21) 0.7794 0.3 0.99 (0.83, 1.18) 0.9022 0.1 
GIF 0.92 (0.81, 1.04) 0.165 1.4 0.94 (0.83, 1.07) 0.3446 0.9 1.1 (0.96, 1.27) 0.1642 1.4 1.12 (0.97, 1.30) 0.1313 1.5 
FGF5 1.33 (0.89, 1.97) 0.1654 1.4 1.15 (0.76, 1.75) 0.5134 0.7 0.95 (0.61, 1.50) 0.8408 0.2 0.88 (0.55, 1.43) 0.6127 0.5 
FLT3L 1.23 (0.92, 1.66) 0.1682 1.4 1.18 (0.86, 1.61) 0.2983 1 1.05 (0.76, 1.45) 0.7568 0.3 0.96 (0.68, 1.35) 0.82 0.2 
DCN 1.28 (0.90, 1.82) 0.1728 1.4 1.15 (0.79, 1.67) 0.4694 0.7 1.43 (1.02, 2.02) 0.0391 2.1 1.33 (0.93, 1.91) 0.1236 1.5 
CHIT1 1.08 (0.97, 1.20) 0.1769 1.4 1.08 (0.96, 1.20) 0.1908 1.3 1.01 (0.91, 1.12) 0.8861 0.1 1.01 (0.90, 1.13) 0.8693 0.2 
CPB1 1.13 (0.94, 1.36) 0.18 1.3 1.1 (0.90, 1.34) 0.3452 0.9 1.15 (0.95, 1.40) 0.1547 1.4 1.1 (0.89, 1.36) 0.4001 0.8 
CCL3 1.1 (0.95, 1.27) 0.1882 1.3 1.05 (0.90, 1.22) 0.5275 0.6 1.13 (0.91, 1.39) 0.2599 1.1 1.05 (0.84, 1.30) 0.6787 0.4 
CD84 1.23 (0.90, 1.67) 0.1894 1.3 1.28 (0.93, 1.77) 0.1285 1.5 1.12 (0.81, 1.55) 0.5086 0.7 1.17 (0.83, 1.66) 0.3731 0.9 
UPA_CVD3 1.22 (0.90, 1.65) 0.1925 1.3 1.2 (0.88, 1.63) 0.251 1.1 1.05 (0.75, 1.47) 0.7792 0.3 1.06 (0.74, 1.53) 0.7324 0.3 
AXL 1.23 (0.90, 1.70) 0.1933 1.3 1.15 (0.82, 1.62) 0.4106 0.8 1.14 (0.85, 1.54) 0.388 0.9 1.08 (0.79, 1.48) 0.6297 0.5 
TFPI 1.26 (0.87, 1.82) 0.2131 1.2 1.25 (0.85, 1.84) 0.2569 1.1 0.98 (0.71, 1.35) 0.8866 0.1 0.96 (0.68, 1.35) 0.8106 0.2 
SCGB3A2 1.09 (0.95, 1.26) 0.216 1.2 1.09 (0.94, 1.27) 0.2515 1.1 1.04 (0.89, 1.22) 0.6438 0.5 0.99 (0.83, 1.17) 0.8647 0.2 
ANG1 1.08 (0.95, 1.24) 0.2223 1.2 1.09 (0.95, 1.25) 0.2388 1.2 1.06 (0.92, 1.21) 0.4174 0.8 1.08 (0.93, 1.26) 0.302 1 
EGFR 0.77 (0.50, 1.18) 0.2258 1.2 0.83 (0.53, 1.31) 0.4258 0.8 0.77 (0.53, 1.10) 0.1504 1.4 0.8 (0.55, 1.18) 0.2607 1.1 
DNER 0.8 (0.56, 1.15) 0.2294 1.2 0.85 (0.58, 1.25) 0.4125 0.8 0.41 (0.25, 0.67) 0.0003 3.6 0.43 (0.26, 0.72) 0.0012 3.2 
HO1 1.23 (0.88, 1.72) 0.2335 1.2 1.41 (0.99, 2.01) 0.0587 1.9 1.02 (0.73, 1.41) 0.9233 0.1 1.01 (0.71, 1.43) 0.9632 0 
TRANCE 0.88 (0.70, 1.10) 0.2543 1.1 0.89 (0.70, 1.12) 0.3111 1 0.83 (0.64, 1.08) 0.1626 1.4 0.78 (0.59, 1.04) 0.0863 1.7 
PIGR 1.44 (0.76, 2.73) 0.2581 1.1 1.6 (0.82, 3.13) 0.1693 1.4 1.89 (1.05, 3.39) 0.0333 2.1 1.9 (1.01, 3.57) 0.048 2 
PDGFSUBUNITA 1.09 (0.93, 1.26) 0.2869 1.1 1.11 (0.95, 1.31) 0.1923 1.3 1.03 (0.89, 1.18) 0.7228 0.4 1.06 (0.91, 1.23) 0.4793 0.7 
THPO 1.18 (0.87, 1.60) 0.2963 1 1.18 (0.86, 1.63) 0.2984 1 1.09 (0.80, 1.50) 0.5843 0.5 1.11 (0.80, 1.56) 0.5249 0.6 
CTRC 0.91 (0.77, 1.09) 0.3048 1 0.94 (0.78, 1.13) 0.496 0.7 0.99 (0.83, 1.19) 0.9303 0.1 1.03 (0.85, 1.26) 0.7581 0.3 
CNTN1 0.85 (0.62, 1.16) 0.3131 1 0.86 (0.62, 1.19) 0.3602 0.9 0.75 (0.54, 1.02) 0.0654 1.8 0.76 (0.54, 1.05) 0.0996 1.6 
CXCL5 1.05 (0.96, 1.15) 0.3253 1 1.03 (0.94, 1.14) 0.4934 0.7 1 (0.90, 1.11) 0.9813 0 1 (0.89, 1.12) 0.9958 0 
IL17RA 1.1 (0.90, 1.35) 0.3346 1 1.1 (0.89, 1.36) 0.3577 0.9 0.95 (0.74, 1.23) 0.7123 0.4 0.93 (0.71, 1.22) 0.6185 0.5 
PROTEINBOC 1.19 (0.83, 1.71) 0.3396 1 1.17 (0.81, 1.71) 0.4024 0.8 1.54 (1.02, 2.32) 0.0385 2.1 1.59 (1.02, 2.48) 0.0402 2.1 
THBS2 1.26 (0.78, 2.05) 0.3475 0.9 1.11 (0.67, 1.83) 0.6897 0.4 2.47 (1.51, 4.03) 0.0003 3.6 2.33 (1.39, 3.90) 0.0013 3.2 
MCP4 1.1 (0.89, 1.37) 0.3822 0.9 1.07 (0.85, 1.34) 0.5679 0.6 0.97 (0.78, 1.20) 0.7668 0.3 0.99 (0.79, 1.24) 0.9367 0.1 
HAOX1 1.05 (0.93, 1.18) 0.4242 0.8 1.01 (0.89, 1.14) 0.918 0.1 0.91 (0.80, 1.04) 0.1691 1.4 0.87 (0.76, 1.00) 0.0571 1.9 
ADAMTS13 0.79 (0.43, 1.44) 0.4457 0.8 1.08 (0.57, 2.04) 0.8111 0.2 1.32 (0.76, 2.31) 0.3298 1 1.61 (0.86, 3.03) 0.1348 1.5 
GLO1 1.07 (0.89, 1.29) 0.4772 0.7 1.05 (0.86, 1.27) 0.64 0.5 1.11 (0.90, 1.37) 0.348 0.9 1.07 (0.85, 1.34) 0.5722 0.6 
TRAIL 1.14 (0.79, 1.65) 0.4776 0.7 1.12 (0.77, 1.64) 0.5556 0.6 0.45 (0.29, 0.69) 0.0003 3.6 0.42 (0.26, 0.67) 0.0003 3.6 
GH 0.97 (0.89, 1.06) 0.4806 0.7 0.99 (0.90, 1.09) 0.8655 0.2 1.05 (0.95, 1.16) 0.3226 1 1.1 (0.99, 1.23) 0.0665 1.8 
RAGE 1.12 (0.82, 1.53) 0.4918 0.7 1.2 (0.85, 1.68) 0.3013 1 1.25 (0.90, 1.74) 0.1809 1.3 1.31 (0.91, 1.88) 0.1528 1.4 
PSGL1 1.09 (0.84, 1.41) 0.5312 0.6 1.12 (0.84, 1.48) 0.4478 0.8 1.39 (0.92, 2.09) 0.117 1.6 1.48 (0.95, 2.30) 0.0795 1.8 
MARCO 0.9 (0.64, 1.27) 0.5512 0.6 0.96 (0.66, 1.38) 0.8067 0.2 1.09 (0.86, 1.38) 0.467 0.7 1.06 (0.83, 1.35) 0.6562 0.4 
IL13 1.11 (0.79, 1.55) 0.5531 0.6 1.22 (0.86, 1.72) 0.2701 1.1 0.95 (0.62, 1.45) 0.8094 0.2 0.92 (0.59, 1.42) 0.6948 0.4 
CCL28 1.09 (0.81, 1.46) 0.5589 0.6 1.11 (0.82, 1.51) 0.5044 0.7 1 (0.78, 1.30) 0.9758 0 1.09 (0.83, 1.44) 0.5345 0.6 
CXCL1 1.04 (0.91, 1.19) 0.566 0.6 1.03 (0.89, 1.19) 0.7054 0.4 1.05 (0.89, 1.24) 0.5851 0.5 1.05 (0.88, 1.25) 0.6141 0.5 
GDF2 0.95 (0.78, 1.16) 0.613 0.5 1.03 (0.83, 1.27) 0.8145 0.2 1.01 (0.81, 1.26) 0.9631 0 1.1 (0.87, 1.40) 0.4238 0.8 
AZU1 1.06 (0.85, 1.32) 0.618 0.5 1.06 (0.85, 1.34) 0.6042 0.5 1.07 (0.91, 1.25) 0.4075 0.8 1.07 (0.90, 1.26) 0.4452 0.8 
MEPE 1.07 (0.83, 1.38) 0.6191 0.5 0.95 (0.72, 1.26) 0.7171 0.4 0.94 (0.72, 1.23) 0.663 0.4 0.8 (0.60, 1.08) 0.1525 1.4 
IL20RA 0.9 (0.56, 1.44) 0.6494 0.5 0.94 (0.57, 1.54) 0.7927 0.3 1.14 (0.46, 2.81) 0.784 0.3 1.39 (0.54, 3.57) 0.496 0.7 
LPL 0.93 (0.67, 1.29) 0.6713 0.4 0.96 (0.68, 1.35) 0.8206 0.2 0.99 (0.75, 1.30) 0.9345 0.1 1 (0.75, 1.34) 0.9738 0 
LDLRECEPTOR 0.96 (0.78, 1.18) 0.6782 0.4 0.97 (0.78, 1.20) 0.7566 0.3 0.89 (0.70, 1.13) 0.3295 1 0.85 (0.66, 1.09) 0.1969 1.3 
KLK6 1.06 (0.79, 1.42) 0.7023 0.4 0.99 (0.71, 1.38) 0.9555 0.1 0.9 (0.70, 1.14) 0.3731 0.9 0.82 (0.62, 1.09) 0.1705 1.4 
CDH5 1.06 (0.79, 1.41) 0.7034 0.4 0.97 (0.71, 1.32) 0.8371 0.2 1.06 (0.80, 1.42) 0.6711 0.4 1.02 (0.75, 1.38) 0.9126 0.1 
TIE2 1.07 (0.73, 1.58) 0.721 0.4 1.07 (0.72, 1.61) 0.7347 0.3 1.41 (0.90, 2.20) 0.137 1.5 1.35 (0.85, 2.14) 0.2 1.3 
SERPINA12 1.02 (0.93, 1.12) 0.7294 0.3 0.99 (0.90, 1.09) 0.8486 0.2 1.15 (0.98, 1.36) 0.0826 1.7 1.14 (0.96, 1.35) 0.127 1.5 
IL1RL2 0.95 (0.72, 1.26) 0.732 0.3 0.94 (0.71, 1.26) 0.7027 0.4 1.24 (0.90, 1.72) 0.1842 1.3 1.24 (0.88, 1.74) 0.2277 1.2 
IL10RA 1.06 (0.74, 1.53) 0.7411 0.3 1.12 (0.76, 1.63) 0.5672 0.6 1.14 (0.59, 2.21) 0.7014 0.4 1.3 (0.65, 2.60) 0.4622 0.7 
EPCAM 0.98 (0.86, 1.12) 0.7485 0.3 0.96 (0.84, 1.11) 0.6088 0.5 0.97 (0.83, 1.14) 0.7455 0.3 0.94 (0.79, 1.11) 0.4395 0.8 
TNFB 0.96 (0.73, 1.27) 0.7851 0.3 0.98 (0.73, 1.32) 0.9046 0.1 0.83 (0.62, 1.12) 0.222 1.2 0.84 (0.61, 1.14) 0.263 1.1 
DLK1 1.02 (0.84, 1.26) 0.812 0.2 0.88 (0.71, 1.11) 0.2825 1.1 1.1 (0.87, 1.38) 0.4338 0.8 0.96 (0.75, 1.25) 0.7821 0.3 
TRAP 0.97 (0.71, 1.32) 0.8421 0.2 0.98 (0.71, 1.35) 0.8888 0.1 0.86 (0.65, 1.14) 0.3037 1 0.8 (0.60, 1.08) 0.1446 1.5 
TNF 1.02 (0.75, 1.39) 0.8775 0.2 1.05 (0.76, 1.44) 0.7876 0.3 0.99 (0.69, 1.41) 0.9465 0.1 1.03 (0.71, 1.51) 0.8614 0.2 
CCL24 0.99 (0.85, 1.15) 0.8876 0.1 1.04 (0.89, 1.21) 0.6233 0.5 0.97 (0.82, 1.14) 0.6845 0.4 0.96 (0.81, 1.15) 0.668 0.4 
BDNF 1 (0.96, 1.05) 0.9166 0.1 1.01 (0.96, 1.05) 0.8295 0.2 1.03 (0.98, 1.09) 0.2125 1.2 1.05 (0.99, 1.11) 0.095 1.7 
CPA1 1.01 (0.85, 1.20) 0.918 0.1 1 (0.83, 1.20) 0.9837 0 1.06 (0.88, 1.28) 0.5252 0.6 1.02 (0.84, 1.25) 0.8099 0.2 
CD6 0.99 (0.79, 1.24) 0.9181 0.1 1.04 (0.82, 1.31) 0.7607 0.3 0.91 (0.70, 1.19) 0.5062 0.7 0.91 (0.69, 1.22) 0.5401 0.6 
IL1RT2 1.01 (0.77, 1.34) 0.9375 0.1 0.99 (0.74, 1.32) 0.9496 0.1 0.97 (0.72, 1.30) 0.8275 0.2 0.92 (0.67, 1.26) 0.6147 0.5 
CCL22 1 (0.89, 1.14) 0.9398 0.1 1.01 (0.89, 1.15) 0.8543 0.2 1.03 (0.88, 1.19) 0.7421 0.3 1.07 (0.91, 1.25) 0.4181 0.8 
PRSS27 1.01 (0.77, 1.32) 0.9562 0.1 0.88 (0.66, 1.17) 0.3814 0.9 1.4 (1.01, 1.94) 0.0443 2 1.3 (0.92, 1.85) 0.1386 1.5 
*FDR 1% threshold in the discovery phase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 3. Odds ratios (OR) and 95% confidence intervals (CI) for the selected proteins 
(significant in both discovery and replication sets with a false discovery rate of 1%) after adjustment 
for the matching variables (age, sex, and follow-up time), clinical risk factors (smoking, diabetes, 
coronary artery disease, serum creatinine, body mass index, heart rate, anti-hypertensive medication 
use) and correction for multiple comparisons in both discovery and replication sets 
 Protein name Discovery Replication 
 OR (95% CI) P-value OR (95% CI) P-value 
BNP 1.59 (1.38, 1.84) <0.0001 1.78 (1.52, 2.08) <0.0001 
NTPROBNP 1.79 (1.50, 2.14) <0.0001 2.05 (1.66, 2.53) <0.0001 
TRAILR2 2.70 (1.86, 3.92) <0.0001 2.65 (1.72, 4.06) <0.0001 
TNFRSF13B 1.58 (1.21, 2.07) 0.0008 2.30 (1.56, 3.39) <0.0001 
GAL9 2.30 (1.48, 3.57) 0.0002 2.46 (1.53, 3.94) 0.0002 
FGF23 1.48 (1.21, 1.82) 0.0002 1.71 (1.31, 2.22) <0.0001 
TNFRSF10A 2.02 (1.41, 2.90) 0.0001 2.00 (1.32, 3.03) 0.0010 
REN 1.17 (0.98, 1.41) 0.0798 1.36 (1.12, 1.66) 0.0019 
TNFRSF11A 1.73 (1.29, 2.32) 0.0002 1.54 (1.12, 2.11) 0.0074 
GDF15 2.34 (1.72, 3.19) <0.0001 1.58 (1.18, 2.12) 0.0024 
FABP4 1.56 (1.24, 1.96) 0.0001 1.29 (1.03, 1.63) 0.0290 
SLAMF7 1.42 (1.14, 1.77) 0.0019 2.02 (1.39, 2.93) 0.0002 
CCL16 1.37 (1.11, 1.68) 0.0028 1.57 (1.20, 2.05) 0.0009 
TWEAK 0.60 (0.41, 0.87) 0.0075 0.58 (0.42, 0.80) 0.0008 
KIM1 1.30 (1.08, 1.55) 0.0050 1.33 (1.07, 1.65) 0.0093 
CD4 1.67 (1.18, 2.35) 0.0034 1.82 (1.23, 2.70) 0.0026 
VSIG2 1.25 (0.97, 1.60) 0.0857 1.46 (1.06, 2.00) 0.0196 
PON3 0.83 (0.66, 1.03) 0.0962 0.72 (0.57, 0.91) 0.0070 
PLGF 1.86 (1.28, 2.72) 0.0013 1.61 (1.11, 2.34) 0.0119 
MMP12 1.43 (1.14, 1.80) 0.0019 1.35 (1.06, 1.72) 0.0168 
ADM 2.10 (1.46, 3.02) <0.0001 1.40 (1.01, 1.94) 0.0408 
RARRES2 2.42 (1.41, 4.18) 0.0015 1.69 (1.10, 2.58) 0.0158 
CEACAM8 1.47 (1.18, 1.83) 0.0006 1.37 (1.09, 1.74) 0.0081 
SLAMF1 1.28 (1.03, 1.59) 0.0254 1.43 (1.07, 1.90) 0.0142 
TNFR1 1.98 (1.38, 2.84) 0.0002 1.27 (0.93, 1.74) 0.1353 
AGRP 1.65 (1.23, 2.21) 0.0008 1.66 (1.11, 2.48) 0.0139 
TNFR2 1.75 (1.27, 2.42) 0.0007 1.29 (0.97, 1.70) 0.0779 
IGFBP7 1.44 (1.05, 1.96) 0.0219 1.43 (1.06, 1.92) 0.0183 
UPAR 2.27 (1.61, 3.21) <0.0001 1.39 (1.01, 1.93) 0.0464 
PAR1 1.65 (1.17, 2.33) 0.0040 1.53 (1.08, 2.19) 0.0176 
PLC 1.78 (1.17, 2.70) 0.0065 1.42 (0.97, 2.08) 0.0743 
ACE2 1.49 (1.17, 1.89) 0.0012 1.41 (1.08, 1.86) 0.0131 
IL16 1.39 (1.07, 1.80) 0.0131 1.34 (1.04, 1.72) 0.0219 
TFF3 1.52 (1.23, 1.87) 0.0001 1.26 (0.97, 1.63) 0.0834 
OPN 1.81 (1.36, 2.40) <0.0001 1.36 (1.03, 1.79) 0.0304 
SPON2 2.64 (1.35, 5.18) 0.0047 2.04 (1.14, 3.66) 0.0166 
IL4RA 1.42 (1.07, 1.90) 0.0164 1.45 (1.04, 2.02) 0.0299 
TNFRSF14 1.77 (1.26, 2.47) 0.0009 1.26 (0.93, 1.71) 0.1309 
Legend: same as in figure 1. 
 
 Supplemental Table 4. Spearman correlation between the clinical risk score variables and the selected 
biomarkers 
 AGE SMK DM CAD HTN BMI HR CR 
BNP 0.12 0.02 -0.02 0.18 0.06 -0.03 -0.12 0.08 
NTPROBNP 0.13 -0.02 -0.07 0.18 0.07 -0.08 -0.13 0.06 
TRAILR2 0.12 0.10 0.08 0.09 0.07 0.08 -0.01 0.27 
TNFRSF13B 0.00 0.10 0.07 -0.01 0.03 0.09 -0.05 0.13 
GAL9 -0.10 0.18 0.05 -0.04 -0.03 0.14 -0.07 -0.02 
FGF23 0.00 -0.03 0.05 0.06 0.11 0.12 -0.03 0.16 
TNFRSF10A 0.01 0.06 0.08 0.06 0.06 0.14 -0.01 0.10 
REN 0.04 0.06 0.19 0.08 0.18 0.12 -0.02 0.17 
TNFRSF11A 0.08 0.04 0.10 0.06 0.09 0.16 -0.06 0.22 
GDF15 0.15 0.04 0.13 0.09 0.15 0.03 -0.01 0.31 
FABP4 -0.01 -0.04 0.07 -0.02 0.16 0.36 0.05 0.04 
SLAMF7 -0.04 0.02 0.11 0.04 0.04 0.08 0.00 0.10 
CCL16 -0.02 0.03 0.01 0.00 0.10 0.08 -0.01 0.20 
TWEAK -0.01 0.02 -0.11 -0.04 -0.12 -0.04 -0.10 -0.05 
KIM1 0.02 0.03 0.16 0.02 0.09 0.08 0.00 0.12 
CD4 -0.11 0.20 0.10 -0.01 -0.06 0.10 -0.05 0.00 
VSIG2 0.03 0.11 0.15 0.00 0.03 0.00 -0.07 0.14 
PON3 -0.05 0.07 -0.08 -0.13 -0.18 -0.26 -0.08 -0.11 
PLGF 0.13 0.05 0.03 0.08 0.04 0.05 -0.05 0.34 
MMP12 0.09 0.12 0.07 0.15 0.12 -0.01 -0.03 0.20 
ADM 0.05 0.07 0.03 0.05 0.07 0.20 -0.04 0.16 
RARRES2 -0.01 0.06 0.00 -0.03 0.09 0.12 0.00 0.14 
CEACAM8 0.17 -0.07 -0.02 0.06 0.12 0.06 0.03 0.19 
SLAMF1 -0.08 0.10 0.09 0.03 0.01 0.13 -0.04 0.15 
TNFR1 0.10 0.06 0.06 0.00 0.10 0.10 -0.04 0.28 
AGRP 0.10 -0.05 0.05 0.10 0.08 -0.02 -0.02 0.22 
TNFR2 0.05 0.09 0.05 0.00 0.07 0.06 -0.05 0.20 
IGFBP7 0.05 0.03 0.06 0.01 0.08 0.03 -0.07 0.18 
UPAR 0.07 0.04 0.01 0.03 0.08 0.04 -0.02 0.09 
PAR1 -0.05 0.17 0.09 -0.08 -0.08 0.07 -0.01 0.01 
PLC 0.12 -0.03 0.00 0.03 0.11 0.13 -0.06 0.33 
ACE2 -0.09 0.12 0.10 0.03 -0.04 0.08 -0.03 0.02 
IL16 0.00 0.08 0.03 -0.04 0.02 0.14 -0.05 0.03 
TFF3 0.08 0.02 0.06 0.02 0.16 -0.06 0.01 0.24 
OPN 0.01 0.14 0.00 0.03 0.00 0.01 -0.07 0.08 
SPON2 -0.16 0.22 0.04 -0.06 -0.14 0.04 -0.12 -0.09 
IL4RA -0.04 0.15 0.06 -0.01 -0.10 0.01 -0.10 0.01 
TNFRSF14 0.11 0.05 0.06 0.00 0.09 0.03 -0.01 0.25 
Legend: SMK, smoking, DM, diabetes mellitus; CAD, coronary artery disease; HTN, hypertension; 
BMI, body mass index; HR, heart rate; CR, creatinine. 
 
Supplemental Table 5. Final adjusted stepwise forward model starting with the 39 proteins 
independently selected in both discovery and replication sets (discovery and replication sets “pooled” 
for this analysis) 
Biomarker OR (95%CI) P-value 
BNP 1.43 (1.25-1.64) <0.0001 
TWEAK 0.38 (0.28-0.50) <0.0001 
NTPROBNP 1.39 (1.17-1.66) <0.0001 
REN 1.28 (1.10-1.49) 0.001 
TRAILR2 1.56 (1.13-2.15) 0.007 
PON3 0.78 (0.65-0.94) 0.008 
CCL16 1.27 (1.06-1.53) 0.008 
SLAMF1 1.24 (1.01-1.52) 0.036 
Model adjusted for matching variables (age, sex, cohort, phase, follow-up time) and clinical variables 
(smoking, diabetes, history of coronary artery disease, serum creatinine, body mass index, systolic 
blood pressure, use of antihypertensive medication, and heart rate (the clinical model) with a p-value 
for inclusion set at 0.05. 
AUC clinical model =0.68; AUC clinical model + final protein selection =0.78 (∆AUC p-value 
<0.001). 
Legend: BNP, brain natriuretic peptide; TWEAK, tumor necrosis factor (Ligand) superfamily, 
member 12; NTPROBNP, N-terminal prohormone brain natriuretic peptide; REN, renin; TRAILR2, 
TNF-related apoptosis-inducing ligand receptor 2; PON3, paraoxonase; CCL16, C-C motif 
chemokine 16; SLAMF1, signalling lymphocytic activation molecule. 
 Supplemental Table 6. Nodes of induced network linking the top proteins to incident heart failure. 
Level Name 
(sorted by) 
Uniprot 
ID 
Protein / Gene Cluster 
seed ACE2 Q9BYF1 Angiotensin-converting enzyme 2 Blood pressure regulation 
seed ADM P35318 Adrenomedullin Blood pressure regulation 
seed AGRP O00253 Agouti-related protein Metabolism 
seed BNP P16860 Natriuretic peptides B / N-terminal prohormone brain 
natriuretic peptide 
Blood pressure regulation 
seed CCL16 O15467 C-C motif chemokine 16 Inflammation and apoptosis 
seed CD4 P01730 T-cell surface glycoprotein CD4 Inflammation and apoptosis 
seed CEACAM8 P31997 Carcinoembryonic antigen related cell adhesion molecule 
8 
Extracellular matrix remodelling, angiogenesis and growth 
seed FABP4 P15090 Fatty acid-binding protein, adipocyte Metabolism 
seed FGF23 Q9GZV9 Fibroblast growth factor 23 Blood pressure regulation 
seed GAL9 O00182 Galectin-9 Extracellular matrix remodelling, angiogenesis and growth 
seed GDF15 Q99988 Growth/differentiation factor 15 Extracellular matrix remodelling, angiogenesis and growth 
seed IGFBP7 Q16270 Insulin-like growth factor-binding protein 7 Inflammation and apoptosis 
seed IL16 Q14005 Pro-interleukin-16 Inflammation and apoptosis 
seed IL4RA P24394 Interleukin-4 receptor subunit alpha Inflammation and apoptosis 
seed KIM1 Q96D42 Kidney injury molecule 1/Hepatitis A virus cellular 
receptor 1 
Inflammation and apoptosis 
seed MMP12 P39900 Matrix metalloproteinase-12 Extracellular matrix remodelling, angiogenesis and growth 
seed OPN P10451 Osteopontin Extracellular matrix remodelling, angiogenesis and growth 
seed PAR1 P25116 Proteinase-activated receptor 1 / Coagulation Factor II 
Thrombin Receptor 
Blood pressure regulation 
seed PLC P98160 Perlecan Extracellular matrix remodelling, angiogenesis and growth 
seed PLGF P49763 Placenta growth factor Extracellular matrix remodelling, angiogenesis and growth 
seed PON3 Q15166 Paraoxonase 3 Metabolism 
seed RARRES2 Q99969 Retinoic acid receptor responder 2 Metabolism 
seed REN P00797 Renin Blood pressure regulation 
seed SLAMF1 Q13291 Signaling lymphocytic activation molecule Inflammation and apoptosis 
seed SLAMF7 Q9NQ25 SLAM family member 7 Inflammation and apoptosis 
seed SPON2 Q9BUD6 Spondin 2 Extracellular matrix remodelling, angiogenesis and growth 
seed TFF3 Q07654 Trefoil factor 3 Inflammation and apoptosis 
seed TNFR1 P19438 Tumor necrosis factor receptor 1 Inflammation and apoptosis 
seed TNFR2 P20333 Tumor necrosis factor receptor 2 Inflammation and apoptosis 
Level Name 
(sorted by) 
Uniprot 
ID 
Protein / Gene Cluster 
seed TNFRSF10A O00220 Tumor necrosis factor receptor superfamily member 10A Inflammation and apoptosis 
seed TNFRSF11A Q9Y6Q6 Tumor necrosis factor receptor superfamily member 11A Inflammation and apoptosis 
seed TNFRSF13B O14836 Tumor necrosis factor receptor superfamily member 13B Inflammation and apoptosis 
seed TNFRSF14 Q92956 Tumor necrosis factor receptor superfamily member 14 Inflammation and apoptosis 
seed TRAILR2 O14763 TNF-related apoptosis-inducing ligand receptor 2 Inflammation and apoptosis 
seed TWEAK O43508 Tumor necrosis factor (Ligand) superfamily, member 12 Inflammation and apoptosis 
seed UPAR Q03405 Urokinase plasminogen activator surface receptor Extracellular matrix remodelling, angiogenesis and growth 
seed VSIG2 Q96IQ7 V-set and immunoglobulin domain-containing protein 2 Inflammation and apoptosis 
intermediate AGT P01019 Angiotensinogen Blood pressure regulation 
intermediate Angiotensin I 
 
Angiotensin I Blood pressure regulation 
intermediate Angiotensin II 
 
Angiotensin II Blood pressure regulation 
intermediate CERCAM Q5T4B2 Inactive glycosyltransferase 25 family member 3 / 
Cerebral endothelial cell adhesion molecule 
Extracellular matrix remodelling, angiogenesis and growth 
intermediate CIP2A Q8TCG1 Cancerous inhibitor of PP2A Inflammation and apoptosis 
intermediate DNAJA1 P31689 DnaJ homolog subfamily A member 1 Inflammation and apoptosis 
intermediate ERAP1 Q9NZ08 Endoplasmic reticulum aminopeptidase 1 Inflammation and apoptosis 
intermediate FAP Q12884 Prolyl endopeptidase FAP Extracellular matrix remodelling, angiogenesis and growth 
intermediate FAS P25445 Fas Cell Surface Death Receptor/ Tumor necrosis factor 
receptor superfamily member 6 
Inflammation and apoptosis 
intermediate FBLN1 P23142 Fibulin 1 Extracellular matrix remodelling, angiogenesis and growth 
intermediate FBN1 P35555 Fibrillin-1 Extracellular matrix remodelling, angiogenesis and growth 
intermediate FUT11 Q495W5 Fucosyltransferase 11 Extracellular matrix remodelling, angiogenesis and growth 
intermediate GALNT18 Q6P9A2 Polypeptide N-Acetylgalactosaminyltransferase 18 Extracellular matrix remodelling, angiogenesis and growth 
intermediate GHRL Q9UBU3 Ghrelin Metabolism 
intermediate GRN P28799 Granulin/Epithelin Inflammation and apoptosis /Extracellular matrix 
remodelling, angiogenesis and growth 
intermediate HIF1A/ARNT / Hypoxia-inducible factor 1-alpha/Aryl hydrocarbon 
receptor nuclear translocator complex 
 
intermediate HNF1B P35680 Hepatocyte nuclear factor 1-beta 
 
intermediate KRT18 P05783 Keratin, type I cytoskeletal 18 Inflammation and apoptosis 
intermediate LAMA1 P25391 Laminin Subunit Alpha 1 Extracellular matrix remodelling, angiogenesis and growth 
intermediate LARGE1 O95461 LARGE xylosyl- and glucuronyltransferase 1 Extracellular matrix remodelling, angiogenesis and growth 
intermediate LTA P01374 Lymphotoxin Alpha Inflammation and apoptosis 
intermediate NAGLU P54802 N-Acetyl-Alpha-Glucosaminidase Extracellular matrix remodelling, angiogenesis and growth 
intermediate NFkB / Nuclear factor NF-kappa-B complex Inflammation and apoptosis 
Level Name 
(sorted by) 
Uniprot 
ID 
Protein / Gene Cluster 
intermediate NID1 P14543 Nidogen 1/Entactin Extracellular matrix remodelling, angiogenesis and growth 
intermediate NID2 Q14112 Nidogen 2/Osteonidogen Extracellular matrix remodelling, angiogenesis and growth 
intermediate S100A10 P60903 S100 Calcium Binding Protein A10 Inflammation and apoptosis 
intermediate SERTAD3 Q9UJW9 SERTA domain-containing protein 3 
 
intermediate SLC1A1 P43005 Excitatory amino acid transporter 3 Inflammation and apoptosis 
intermediate SSR4 P51571 Translocon-associated protein subunit delta Inflammation and apoptosis 
intermediate STAT6 P42226 Signal Transducer And Activator Of Transcription 6 
dimer 
 
intermediate TNFRSF25 Q93038 TNF Receptor Superfamily Member 25 Inflammation and apoptosis 
intermediate TNFSF10 P50591 TNF Superfamily Member 10 Inflammation and apoptosis 
intermediate TNFSF13 O75888 Tumor Necrosis Factor (Ligand) Superfamily, Member 
13 
Inflammation and apoptosis 
intermediate TP53 P04637 Tumor Protein P53 
 
intermediate TP73 O15350 Tumor Protein P73 
 
intermediate TRADD Q15628 Tumor necrosis factor receptor type 1-associated DEATH 
domain protein 
Inflammation and apoptosis 
intermediate TRAF2 Q12933 TNF Receptor Associated Factor 2 Inflammation and apoptosis 
intermediate TRAF3 Q13114 TNF Receptor Associated Factor 3 Inflammation and apoptosis 
intermediate TRAF5 O00463 TNF receptor-associated factor 5 Inflammation and apoptosis 
intermediate VEGFA P15692 Vascular Endothelial Growth Factor A Extracellular matrix remodelling, angiogenesis and growth 
 
 
  
Supplemental Table 7. Results of overrepresentation analysis on GO for selected top proteins against all measured proteins as background. 
GO process and 
function 
Number 
of 
proteins 
in GO 
item 
Number of 
proteins on 
OLINK 
panel 
Proteins in GO process on OLINK 
panel 
(with  Entrez Gene ID) 
Number 
of 
selected 
proteins 
Selected proteins 
(with  Entrez Gene ID) 
p-value 
death receptor activity 
(GO:0005035) 
11 5 7132     TNFRSF1A : TNF receptor 
superfamily member 1A 
7133     TNFRSF1B : TNF receptor 
superfamily member 1B 
8792     TNFRSF11A : TNF receptor 
superfamily member 11a 
8797     TNFRSF10A : TNF receptor 
superfamily member 10a 
8764     TNFRSF14 : TNF receptor 
superfamily member 14 
5 
(100.0%) 
7132     TNFRSF1A : TNF receptor 
superfamily member 1A 
7133     TNFRSF1B : TNF receptor 
superfamily member 1B 
8792     TNFRSF11A : TNF receptor 
superfamily member 11a 
8797     TNFRSF10A : TNF receptor 
superfamily member 10a 
8764     TNFRSF14 : TNF receptor 
superfamily member 14 
5.47E-05 
tumor necrosis factor-
activated receptor 
activity (GO:0005031) 
9 4 7132     TNFRSF1A : TNF receptor 
superfamily member 1A 
7133     TNFRSF1B : TNF receptor 
superfamily member 1B 
8792     TNFRSF11A : TNF receptor 
superfamily member 11a 
8764     TNFRSF14 : TNF receptor 
superfamily member 14 
4 
(100.0%) 
7132     TNFRSF1A : TNF receptor 
superfamily member 1A 
7133     TNFRSF1B : TNF receptor 
superfamily member 1B 
8792     TNFRSF11A : TNF receptor 
superfamily member 11a 
8764     TNFRSF14 : TNF receptor 
superfamily member 14 
0.000409 
renal system process 
(GO:0003014) 
116 5 133     ADM : adrenomedullin 
2149     F2R/PAR1 : coagulation 
factor II thrombin receptor 
4879     NPPB : natriuretic peptide B 
5155     PDGFB : platelet derived 
growth factor subunit B 
5972     REN : renin 
4 
(80.0%) 
133     ADM : adrenomedullin 
2149     F2R/PAR1 : coagulation 
factor II thrombin receptor 
4879     NPPB : natriuretic peptide B 
5972     REN : renin 
0.001827 
  
GO process and 
function 
Number 
of 
proteins 
in GO 
item 
Number of 
proteins on 
OLINK 
panel 
Proteins in GO process on OLINK 
panel 
(with  Entrez Gene ID) 
Number 
of 
selected 
proteins 
Selected proteins 
(with  Entrez Gene ID) 
p-value 
regulation of systemic 
arterial blood pressure 
(GO:0003073) 
91 8 133     ADM : adrenomedullin 
1522     CTSZ : cathepsin Z 
2149     F2R/PAR1 : coagulation 
factor II thrombin receptor 
4879     NPPB : natriuretic peptide B 
5155     PDGFB : platelet derived 
growth factor subunit B 
5972     REN : renin 
6648     SOD2 : superoxide 
dismutase 2 
59272   ACE2 : angiotensin I 
converting enzyme 2 
5 
(62.5%) 
133     ADM : adrenomedullin 
2149     F2R/PAR1 : coagulation 
factor II thrombin receptor 
4879     NPPB : natriuretic peptide B 
5972     REN : renin 
59272   ACE2 : angiotensin I 
converting enzyme 2 
0.002169 
Supplemental Figure 1. Sample handling diagram
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 2. The two major clusters inflammatory/apoptosis and blood pressure regulation 
were also detected as the main groups using the ClueGO network analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental addenda 1. Material and Methods for the Olink® technology 
Proteins were measured using the Olink® CVDII, CVDIII, and Inflammation panels* (Olink 
Proteomics AB, Uppsala, Sweden) according to the manufacturer's instructions. The Proximity 
Extension Assay (PEA) technology used for the Olink protocol has been well described (Assarsson et 
al, 2014; accessible at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0095192), 
and enables 92 analytes to be analyzed simultaneously, using 1µL of each sample. In brief, pairs of 
oligonucleotide-labeled antibody probes bind to their targeted protein, and if the two probes are 
brought in close proximity the oligonucleotides will hybridize in a pair-wise manner. The addition of 
a DNA polymerase leads to a proximity-dependent DNA polymerization event, generating a unique 
PCR target sequence. The resulting DNA sequence is subsequently detected and quantified using a 
microfluidic real-time PCR instrument (Biomark HD, Fluidigm). The resulting Ct-data is then quality 
controlled and normalized using a set of internal and external controls. The final assay read-out is 
presented in Normalized Protein eXpression (NPX) values, which is an arbitrary unit on a log2-scale 
where a high value corresponds to a higher protein expression. The four internal controls are designed 
to mimic and monitor the different steps of the PEA. They consist of two non-human proteins with 
matching antibody-probes that functions as incubation/immuno controls, an IgG antibody with two 
matching probes attached to it that functions as an extension control and a complete double-stranded 
amplicon that function as detection control. The internal controls are introduced to all samples as well 
as to the external controls. The external controls consist of a triplicate of negative controls used to 
calculate the limit of detection (LOD), as well as a triplicate of interplate controls (IPCs) containing 
92 sets of antibodies with both matching probes for each assay attached to them that are used for 
normalization. For each sample and assay NPX is calculated by the following equations: 1. Ct(analyte) – 
Ct(extension control) =dCt(analyte) (to decrease technical variation) 2. dCt(analyte) – Ct(median IPC)=ddCt(analyte) (to 
improve inter plate variation) 3. Correction factor(analyte) – ddCt(analyte) =NPX(analyte) (for more intuitive 
data). The correction factor is a set variable unique for each assay and reagent lot.  
Quality control of the data is performed in two steps: First, the standard deviation for each of the 
incubation/immuno controls and the detection control is calculated for each run. A run will only pass 
quality control if the standard deviation for each of the controls is below 0.2. Secondly, each sample is 
quality controlled using incubation control 2 and the detection control. The run median of each of the 
controls is calculated and all samples within the run is compared to that. Samples that fall more than 
+/- 0.3 NPX from the plate median with regards to these two controls will fail the quality control and 
receive a QC warning in the data output file.  
All assay validation data (detection limits, intra- and inter-assay precision data, etc.) are available on 
manufacturer's website (www.olink.com). 
* Previously branded as Olink® Multiplex panels. 
An example of a QC-plot is provided below: 
  
Technichal description Olink Proximity Extension Assay 
Overview 
Olink Proteomics has developed a unique protein detection system called Proximity Extension Assay 
(PEA), which enables highly specific and sensitive multiplex immunoassays for the detection of 92 
different proteins in 90 samples simultaneously, generating 9260 data points in a single run. These 
proteins can be measured in a large variety of human sample types using as little as one microliter 
volume of sample. To date, >25 different biological matrices have been tested, all of which have 
proven compatible with PEA. Olink Proteomics currently offers assays for more than 977 proteins. 
During PEA, protein targets are ID-tagged by unique DNA amplicons that are subsequently detected 
and quantified by real-time PCR using Fluidigm’s BioMark HD system. In doing so, the platform 
harnesses the highly parallel nature of Fluidigm’s Dynamic Array IFC (Integrated Fluidic Circuit) 
technology, bringing the assays to the high throughput, reproducibility and superior sensitivity realm 
of the BioMark HD. 
Measurements performed with the Proseek® Multiplex assays are semi-quantitative, where changes in 
protein levels in one group or population are quantified relative to another. The assays generate 
quantitation cycle (Cq) values that are then normalized and converted to Olink’s arbitrary Normalized 
Protein eXpression (NPX) unit, which can be used for further statistical analyses. NPX gives relative 
quantification. NPX is on a log2 scale. NPX should be compared between samples for each 
assay separately. 
The analytical performance is thoroughly validated during product development to ensure the highest 
standards of sensitivity, precision, specificity and dynamic range. Since traceable calibrators are not 
yet available for all proteins in Olink’s portfolio, performance is evaluated by using full length 
recombinant proteins as well as well characterized normal and diseased plasma/serum samples. 
Repeatability of the measurements is reflected by an average intra-assay variation of 5-10%CV, and 
inter-assay variation 10-20%CV.  
Multiple head-to-head comparisons have been performed against golden-standard single-plex ELISA 
assays in clinical settings (e.g. NT-pro-BNP, OPN, ST2). So far, these tests have demonstrated strong 
positive correlation, and have indicated similar, and sometimes superior, levels of sensitivity for 
Olink’s PEA-based assays.  
The real strength of Olink’s technology is that it offers a high-throughput capacity coupled to a 
growing list of analytes, therefore placing the platform in a strong position for biomarker selection. 
Furthermore, the development of new multiplex assays is very rapid thank to a conjugation procedure 
that works well on all antibody subtypes tested so far, universal incubation conditions and minimal 
probe concentrations used in our assays. Olink Proteomics currently offers 12 pre-designed 92-plex 
panels. 
Detailed technical description 
Measurements 
1. Accuracy and reproducibility of the measurements:  
Olink’s multiplex assays are validated following the standard procedure for immunoassays. 
Proseek® Multiplex measurements are semi-quantitative, where changes in protein levels are 
determined and compared for each protein separately. Due to the nature of relative quantification, no 
calibration standards are needed leaving room for more biological samples on the plate and, thus, 
higher throughput.  
The output from the Proseek Multiplex protocol is in quantitation cycles (Cq) produced by the 
BioMark’s Real-Time PCR Software. To minimize variation within and between runs, the data is 
normalized using both an internal control (Extension Control) and an Inter-Plate Control (IPC), and 
data is transformed using a pre-determined correction factor. The pre-processed data will be in the 
arbitrary unit NPX (Normalized Protein eXpression), which can be used for further statistical 
analyses. 
2. Volume:  
As little as 1 l of sample is required to analyse 92 proteins in a single measurement. The amount of 
data generated increases proportionally with the volume of analysed sample, so that 2 l produces 
data for 184 proteins and so forth. 
3. Number of proteins:  
92 proteins are quantified for each sample in a single run. 
4. Sample types:  
Proseek® Multiplex assays are designed for detection of proteins in complex human biofluids. 
Proseek® Multiplex assays are validated using both EDTA plasma and serum samples. Furthermore, 
a wide range of additional sample types are compatible with the technology, such as citrate and 
heparin plasma, CSF, urine, saliva, tissue and cell lysates, cell culture media, dried blood spots and 
many more. See Table 1 at the end of this document for information about some of the sample types 
that have been analyzed so far. Olink is open to discussion and exploration of untested sample types. 
5. Correlation and agreement:  
Correlation studies have been carried out for a subset of proteins to compare Olink’s Proseek® 
Multiplex assays to commercial singleplex ELISA/conventional analyses in clinical settings. Olink 
assays have so far displayed high correlations with these established tests, both in Olink’s own 
Service Laboratory and external, customer-led evaluations, demonstrating the accuracy and 
parallelism of the PEA technology. PEA is described by a peer-reviewed publication in PLOS one: 
Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent 
Scalability. Assarsson and Lundberg et al., 2014. 
6. Validation:  
During the validation procedure, Olink analyzes matched plasma (three different anti-coagulants) and 
serum samples, and reports their respective protein levels relative to the measurements in EDTA 
plasma. This varies for each biomarker and is presented in the Validation Data package for each 
panel. Intra- and inter-assays precision values are also determined for each protein and presented in 
the Validation Data Packages which can be found on http://www.olink.com/proseek-multiplex/. 
In a recent pilot wellness study, EDTA plasma was taken from 88 well-characterized individuals at 
three different time points (every 3 months) and each sample was analyzed using multiple Proseek® 
Multiplex panels. A large proportion of biomarkers correlated significantly well across the different 
time points for each individual, while some proteins revealed distinct expression patterns that varied 
with time. It is also worth mentioning that the inflammation panel was able to identify the signs of 
infection and single out an individual who had been suffering from illness during one of the three time 
points (data not shown).  
These data further strengthen the case for the robustness of the technology and its potential for future 
longitudinal studies. 
7. Information:  
The platform was recently used to investigate the effects of freezer storage, chronological age at 
sampling, season and month of the year on the abundance levels of 108 proteins in 380 plasma 
samples collected from 106 Swedish women: “Effects of Long-Term Storage Time and Original 
Sampling Month on Biobank Plasma Protein Concentrations” Enroth et al., 2016.  
The study found that storage time can explain 4.8-34.9% of the observed variance, and that the 
chronological age at sample collection after adjustment for storage-time explains 1.1-33.5% of the 
observed variance.  
Another recent study performed at the Karolinska Institute, using samples from the BBMRI BioBank 
in Stockholm, found that proteins are stable for consistent measurements by PEA, even after 8 short, 
successive freeze-thaw cycles (manuscript in preparation). 
 
The first Olink panel was launched on the 1st of March 2013 and since then the technology has been 
used to analyse over 235 000 samples. This has so far led to 57 publications, in the form of 
technology reviews and customer applications, demonstrating that Olink’s semi-quantitative approach 
for measuring biomarker levels is approved by referees. More publications are in the pipeline as Olink 
continues to analyse protein biomarkers for life science researchers around the world. For a complete 
list of publications see; http://www.olink.com/data-you-can-trust/publications/ 
Olink will work closely with customers to produce smaller and focused custom panels, to support the 
future development of diagnostic tools based on clinically relevant protein signatures.   
Finally, with the help of bio-informatics tools, Olink proteomics is currently developing ways of 
extending the biological information provided about the proteins in each panel. In doing so, Olink 
intends to go beyond the simple provision of technology and reagents by simultaneously catering 
knowledge for the field of protein biomarker discovery. Olink Proteomics provides first-class support 
to our customers. With our unparalleled experience and skills working with Proseek® Multiplex 
panels, the support team quickly delivers the best assistance, free of charge. Olink Proteomics also 
offers professional statistical analysis services. Our in-house team of biostatisticians can help you 
with customized statistical analyses tailored to your requirements. 
All assay validation data (detection limits, intra- and inter-assay precision data, etc) are available on 
manufacturer's website (www.olink.com). 
Instrumentation 
1. Automation:  
The Fluidigm BioMark HD combined with a controller or Juno is able to load all reagents into the 
microfluidic circuits and can be left to operate protocols unattended during the run. The Dynamic 
Arrays have an integrated network of channels, chambers and valves that automatically combine the 
reactions, conserving time, reagents and sample volumes. Initial pipetting is needed to pipette samples 
and reagents into the micro-well section of the dynamic arrays. Automatic sample and assay mixing 
of Fluidigm integrated fluidic circuit (IFCs) reduces pipetting by 95% compared to conventional PCR 
microplate-based systems. The IFC is subsequently placed in the controller (either HX or Juno). The 
samples do not come in contact with the interface plate which is within the controllers. However, it is 
possible to remove the interface plate and clean with 70% Ethanol as an additional measure between 
runs. Furthermore, it is possible to automate this using liquid handling instruments as the dynamic 
arrays have a Society for Biomolecular Sciences (SBS)-compatible format enabling manual and/or 
384-well plate format handling and standard dispensing equipment. 
By using Fluidigm 96.96 IFCs it is possible to analyse 90 samples + 6 controls in a single run on the 
BioMark HD. At a rate of 3 to 4 IFCs per day, the platform is largely capable of supporting the 
proposed scale of proteomic studies. Dedicated staff can achieve up to 360 samples per day (4 IFCs), 
which translates into 4 x 9216 = 36864 data points in one day per BioMark HD system. 
 
2. Accuracy and Reproducibility:  
The repeatability and reproducibility of Olink multiplex assays is determined by using spiked and 
unspiked serum and plasma samples. These reference samples are generated to cover a wide 
concentration range for each protein target in order to mimic large biological variation, and are 
analysed by several (external) operators/service providers. Olink assays display an average intra-assay 
variation of 5-10% and a 10-20% inter-assay variation. The variation between runs is naturally 
slightly higher, with the highest variation observed for assays that measure samples close to the Limit 
of Detection (LOD). 
Sample types: 
Table 1. Assay detectability in different sample types: Number of proteins detected in healthy blood 
donors 
Sample Type 
Panels 
CVD II CVD III ONC II INF I NEU I 
Whole blood NT NT NT NT NT 
Plasma EDTA 
AS               
99% in >75%    
of samples 
AS               
98% in >75%     
of samples 
AS                
100% in 
>75% of 
samples 
AS                 
80% in >75%     
of samples 
AS 
100% in 
>75% of 
samples 
Plasma Heparin AS AS AS AS AS 
Plasma Citrate AS AS AS AS AS 
Serum 
AS                              
97% in >75%    
of samples 
AS                             
99% in >75%       
of samples 
AS                                 
100% in 
>75% of 
samples 
AS                                 
82% in >75% 
of samples 
AS              
98% in 
>75%       of 
samples 
Urine NT NT NT 
AS                      
37% in >75% 
of samples 
NT 
PBMC NT NT NT 
AS 
73% in >75% 
of samples 
NT 
 
  
Additional sample-types include, but are not limited to: 
CSF 
AS                   
70% in >75% 
samples  
AS                   
61% in >75% 
samples  
AS                   
76% in >75% 
samples  
AS                   
62% in >75% 
samples  
AS                   
85% in 
>75% 
samples  
Exosomes  
AS 
48% in >75% 
samples  
(plasma 
origin) 
AS 
38% in >75% 
samples 
(plasma 
origin) 
AS 
37% in >75% 
samples 
(cell origin) 
AS                       
27% in >75% 
samples 
(cell origin) 
NT 
Saliva NT NT NT 
AS                    
63% in >75% 
of samples  
NT 
Synovial fluid 
AS                    
46% in >75%    
of samples  
NT NT  
AS                    
41% in >75%    
of samples  
NT 
Cell lysates 
AS                    
33% in >75%    
of samples  
AS                     
34% in >75%    
of samples 
AS                    
41% in >75%    
of samples  
AS                     
38% in >75%    
of samples 
NT 
Tissue lysates NT NT NT 
AS 
79 % in 
>75% 
samples 
AS 
86% in 
>75% 
samples 
Cell culture supernatants  NT NT 
AS                      
34% in >75%      
of samples 
AS                       
47% in >75% 
samples 
NT 
Dried blood spots NT NT NT 
AS 
73% in >75%      
of samples 
AS 
54% in 
>75%      of 
samples 
 
AS - Run in Analysis Service 
NT - Not Tested 
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NPX, QC and CV 
Calculation of NPX 
Normalization of the Ct values derived from the qPCR detection step improves precision and makes 
data more intuitive (higher value = higher protein concentration). NPX (Normalized Protein 
eXpression) represents the relative signal (on log2 scale) and is used for downstream statistical 
analyses.  
1. Extension Control:  
  Ctanalyte – CtExt Ctrl = dCtanalyte 
2. Interplate Control:  
  dCtanalyte – dCtInterplate Ctrl  = ddCt 
3. Normalization against a correction factor:  
  Correction factor -  ddCt = NPX  
• Protein expression changes are measured for each protein separately by relative quantification 
• Even if two different proteins have the same NPX values, their actual concentration may 
differ 
• NPX should be compared between samples within a run for each assay separately 
• NPX cannot be directly compared between runs 
 
Quality control  
Olink has built-in quality controls in all multiplex panels. Each 92-plex panel contains 96 assays. Four 
of those are internal controls that allow for an in-process quality control designed to monitor different 
steps of the protocol: immuno reaction, extension and amplification/ detection.  
  The two incubation controls consist of two different non-human antigens measured with PEA 
assays: Incubation Control 1 and 2. These controls monitor potential variation in all three 
steps of the reaction. 
 The Extension Control is an antibody coupled to both DNA-tags (hence always in proximity). 
This control monitors the extension and amplification/detection step. 
 The Detection Control is a complete double stranded DNA amplicon which does not require 
any proximity binding or extension step. This control monitors the amplification/detection 
step. 
The internal controls are used for both sample and run QC. The quality control of data is performed 
separately for each sample plate. 
 
Sample QC 
Each of the internal controls are spiked into the samples in the same concentration. The signal for 
these are therefore expected to be the same over the plate. Sample QC is performed using the 
Detection Control and Incubation Control 2. Within each run, the levels of these controls are 
monitored for each sample and compared against the median of all samples. If either of the controls 
deviate more than the acceptance criteria allow (see below), the sample is flagged. 
The Extension Control is used in the normalization step and in generation of NPX, and hence not 
included in the quality control of data. 
The IPC cannot flag on the Detection control. This function was removed already from the start, as 
the large number of extensions that is required for the IPC made the IPC to always be a bit behind the 
rest of the samples. I.e., the IPC would always flag on the Detection control. It is however always 
constant, and flagging on the Detection control was therefore excluded. 
Acceptance criteria for passing a sample: 
• Incubation Control 2 and Detection Control deviates < +/- 0.3 NPX from plate median. 
 
Run QC 
The internal controls are used also in the run QC. This QC assesses the variation over the plate for 
each of the Incubation Controls 1 and 2 and the Detection Control. If the variation for one of the 
controls is too large (see below) the entire run is considered unreliable. 
Acceptance criteria for passing a run: 
• Standard deviation of Incubation Control 1 & 2 and Detection Control: < 0.2 NPX. 
• Number of flagged samples: ≤ 1/6 of total number of samples (i.e. ≤ 16 in a full plate). 
 
Correction factor 
The correction factor is calculated during the validation of the panels. It is a pre-determined value, a 
fixed background, used to shift signals to a more intuitive value. Several runs during the validation 
process is used for this. Data from all assays are used but only IPC and negative control are needed 
from the samples. A minimum of 12 runs is performed. All runs should have at least three IPCs and 
three negative controls. Median is used in the final steps of the calculations to make the analysis less 
sensitive for extreme values. 
Calculation of correction factor 
 1.       Normalize using extension control: 
    Ctsample assay (x) – Ctsample assay (ext ctrl) = dCtsample assay (x) 
 2.       Normalize using median IPC (per experiment): 
    dCtsample assay (x) – Median dCtIPC assay (x) = ddCtsample assay (x) 
 3.       Calculate average value for background (per experiment): 
    Average (ddCtbackground assay(x)) = Bg IPC(x) 
 4.       Calculate median value for the background of all assays: 
    Median (Bg IPC(x)) 
Since the background is shifting within an interval, this interval is usually estimated by assuming 
normal distribution and selecting which interval to use. Olink uses a confidence interval of 99% (+/- 
3xSD from the background). As the customer is recommended to run only three background samples 
in every run, this will not be enough to exactly calculate the standard deviation for the background. 
Therefore, we have a fixed value for this, which is selected from the same data as the Correction 
Factor. In contrast to the correction factor, fixed SD has a function and impact on the data. 
Normalization 
Olink NPX Manager has three available methods for data normalization and minimization of 
systematic biases between sample plates. These methods are described below. An important 
concept when deciding on normalization procedure is randomization, which in this context 
applies to the sample placement across the plates. For randomized studies with more than one 
plate, intensity normalization is the default normalization. For other studies, IPC normalization 
is default. 
 
IPC normalization 
Three inter-plate controls (IPC) are included on each plate and run as normal samples. The inter-plate 
control is a pool of 92 antibodies, each with one of the pairs of unique DNA tags on it positioned in 
fixed proximity (i.e. 92 Extension Controls). 
The median of the three IPCs is used as normalizer for each assay, and this compensates for potential 
variation between runs/plates. This method is completely independent on the samples included on the 
plate and is therefore recommended for projects where complete randomization of samples cannot be 
guaranteed. 
 Intensity normalization 
The intensity normalization adjusts the data so that the median NPX for a protein on each plate is 
equal to the overall median. Each plate is adjusted so that the median of all assays is the same on all 
plates. 
 
This method requires that the true median of each plate is the same. One way of ensuring this is to 
randomize the samples beforehand. If there is total randomization, this method outperforms other 
normalization methods. If there are specific types of samples that are only available on certain plates, 
this normalization method should not be used. 
 
Control normalization 
The control normalization works in the same way as the IPC normalization, but with one addition. 
While the IPC adjusts each protein to the level of a reference, the control normalization also adjusts 
the total intensity of entire plates. This is useful if you have plates or projects that differ on average in 
a way that cannot be explained biologically. Control normalization can be used to reduce systematic 
variation in non-randomized studies. This normalization method requires the addition of at least two 
control samples on each plate. 
NOTE This is an optional normalization method that should only be used when standard 
normalizations are not sufficient. 
 
Coefficient of variation 
%CV is calculated using linear NPX values from replicate control samples, for assays detected above 
LOD. 
Intra-CV represents the CV within a plate and inter-CV represents the CV between plates. The 
reported %CV is the mean %CV over all assays. 
Coefficient of Variation = (Standard Deviation / Mean) * 100 
• Reference value for Inter %CV: < 25% 
• Reference value for Intra %CV: < 15% 
 
 
